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Abstract 
 
Photo-translocation makes use of laser light to translocate exogenous materials 
into cells.  It’s applicability as a drug delivery systems (DDS) has not been 
explored.  This proof-of-principle study evaluated the applicability of a home-built 
femtosecond (fs)-laser based photo-translocation system as a DDS, using human 
immunodeficiency virus type-1 (HIV-1) antiretroviral (ARV) drugs as a model.  A 
tightly focused pulsed laser was integrated into a photo-translocation system 
which was set up, validated and used to facilitate the delivery of ARV drugs 
against a concentration gradient into TZM-bl cells.  To ensure preservation of the 
cell’s integrity, cell viability tests were carried out post laser treatment.  An HIV-1 
subtype C envelope-pseudovirus (ZM53) was generated and used in an in vitro 
phenotypic inhibition assay to measure the success of photo-translocation of three 
selected ARV drugs into TZM-bl cells.   
 
The near infrared (NIR) photo-translocation setup was successfully assembled 
and validated, as shown by characterisation of the relevant parameters such as 
pulse duration (10 picoseconds), central wavelength (1063.8 nm) and beam 
quality (1.15).  The optimal functionality of the newly built photo-translocation 
system, as determined by trypan-blue exclusion dye in TZM-bl cells, was 3 doses 
of laser treatment at a power level of 60 mW and an exposure time of 50 ms.  
These parameters were extrapolated to photo-translocation experiments using 
selected ARV drugs.  Photo-translocation of tenofovir and nevirapine resulted in 
enhanced levels of approximately 25% viral inhibition against ZM53 
pseudoviruses.  By contrast, no detectable change in viral inhibition was observed 
vi 
in the photo-translocation of efavirenz.  Cell viability results confirmed that no 
toxicity existed within the laser irradiated cell population with cell viabilities greater 
than 70% at the tested drug concentrations.  Tenofovir was not toxic to the cells at 
the administered concentration of 20 µg/ml.  However, nevirapine (10 µg/ml) and 
efavirenz (14 µg/ml) showed high levels of toxicity after prolonged exposure to the 
cells (48 hours) while laser irradiation and brief (30 minutes) exposure to the drugs 
resulted in significant elevations of cell viability.  Overall, this study demonstrated 
for the first time that laser technology is an efficient, targeted DDS which led to 
elevated therapeutic effects of ARV drugs against HIV-1 pseudoviruses with 
minimal damage to the treated cells in vitro.   
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1. Literature Background 
1.1 Introduction 
In the medical sciences successful delivery of therapeutic, preventative and 
nutritional agents is imperative to the survival of humankind.  There are generally a 
variety of therapeutic agents in the form of (but not limited to) hydrophilic agents 
(Glauser et al., 2014, Patel et al., 2001), nucleic acids including small interfering 
ribonucleic acids (siRNA) (Shen et al., 2012, Chen et al., 2010, Gomes et al., 
2014, Hyukjin Lee et al., 2012), lipids (Szebeni et al., 2011), proteins (van den 
Berg et al., 2011), vaccines (Bolhassani et al., 2011), and other macromolecules.  
Mostly, at molecular levels, these agents are not readily taken up by mammalian 
cells due to the presence of a generally non-permeable membrane lipid bilayer 
which is the outermost layer of all mammalian cells.  The lipid bilayer serves to 
control the movement of molecules in and out of the cell.  Therapeutic drugs have 
to penetrate the cell membrane in order to execute an appropriate therapeutic 
effect at the target site (Bally et al., 1999, Belting et al., 2005).  In in vivo systems, 
drugs have to be transferred from the site of administration to the bloodstream 
before reaching respective target sites.  The rate at which this transfer occurs as 
well as the efficiency of the drug is dependent on the route of administration or the 
drug delivery system (DDS).  Depending on the DDS used, the drug may only be 
partially absorbed into the bloodstream leading to a low bioavailability of the drug 
at the target site (Muller et al., 2004). 
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Drugs are absorbed into the circulatory system depending on their chemical 
properties.  This process can occur either by passive or active diffusion.  During 
passive diffusion drugs move from a region of high concentration to one of a lower 
concentration.  The process of passive diffusion is governed by factors which 
include the size and shape of the molecule, the degree of ionization and the 
solubility of the drug (Levine, 1970).  Active diffusion moves drugs against a 
concentration gradient from a region of low drug concentration to that of a high 
drug concentration (Lennernas et al., 1996), where the transport of drugs is 
assisted by energy in the form of adenosine triphosphate (ATP).  Other methods of 
drug absorption by target cells include, but are not limited to endocytosis, 
exocytosis and pinocytosis.  These two drug transport systems occur in the case 
where large molecules have to cross the cell membrane.  Contrarily, in the case of 
endocytosis the drug is engulfed by the cell membrane followed by the intracellular 
pinching off of the vesicle encasing the drug.  The opposite is exocytosis where 
the cells usually secrete and release substances such as neurotransmitters 
(Farquhar, 1983, Bretscher, 1984, Battey et al., 1999).  Pinocytosis refers to the 
invagination of the cell membrane around a molecule in turn incorporating the drug 
inside the cell (Chillistone, 2014). 
 
Factors that affect the absorption of drugs into the blood stream include product 
bioavailability which involves the speed and extent to which a drug is absorbed; 
the pharmacokinetics of the drug which consist of the metabolism, the distribution 
as well as the elimination of the compound.  The formulation (whether the drug is a 
capsule or tablet etc.) of the drug may also affect its absorption, but when it has 
reached the circulatory system the initial formulation of the drug does not affect its 
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behaviour as it would usually already be in a dissolved state  (Martinez et al., 
2002).  Furthermore, the environmental conditions of the gastrointestinal tract 
(GIT) and the nature of the drug absorbing cell particularly the cells metabolic 
activity and the structure of the cells absorbing surface which also affect the 
absorption of the therapeutic agents (Levine, 1970). 
 
Pharmacogenetics, the study of how the host genetic differences in the metabolic 
pathway of drugs contributes to how individuals respond to drugs must also be 
considered as a factor which contributes significantly to the efficacy of a drug.  
This becomes crucial as host genetic differences cause different individuals and 
populations to respond differently to medication even when administered in the 
same dosages (Lu, 1998).  The human body has various drug targets such as 
receptors (Viola et al., 2008), enzymes (Overall et al., 2006) and proteins 
(Anishetty et al., 2005).  Drugs target these proteins which are involved in a variety 
of cellular events including signal transduction and cell cycle control to induce a 
pharmacological effect.  The genes which code for these targets are genetically 
polymorphic (Chan et al., 2004). 
 
The ability of a drug to be absorbed, distributed and metabolised, and interact with 
its target can be investigated through an understanding of host genetic 
differences.  Genetic factors account for the inter-individual differences observed 
in the variable manner to which individuals respond to drugs (Eichelbaum et al., 
2006).  The majority of orally administered drugs available in the market are 
metabolised by various forms of polymorphic, membrane associated enzymes 
known as cytochromes P450 (CYP) (Evans et al., 1999).  The presence of single 
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nucleotide polymorphisms (SNPs) which are DNA sequence variations in genes 
encoding CYPs are the basis for the genetic variability found in different 
individuals.  These variations alter the activity of the encoded protein compared to 
the wild type sequence.  In such instances, the activity of the protein may be 
reduced due to the genetic polymorphisms while the variation can also result in 
elevated activities of the protein (Evans et al., 1999). 
 
The efficacy of drugs is also dependant on the drugs ability to cross physical 
barriers in order to reach their target site of action.  Physical barriers in the GIT, in 
the form of plasma membrane contain adenosine triphosphate (ATP)-binding 
cassette (ABC) efflux proteins which mediate drug transport as this plays a major 
role in the absorption, bioavailability and elimination of drugs (Chan et al., 2004).  
Genetic polymorphisms which interfere with the expression of these efflux proteins 
or which alter their affinity for substrates are able to result in phenotypic and 
pharmacological effects of the drugs (Eichelbaum et al., 2006).  Host genetic 
effects of how a drug is metabolised, absorbed and eliminated are an important 
factor as they can result in negative clinical effects on individuals being treated as 
the therapeutic doses being administered may not be ideal for the desired 
therapeutic effect with minimal side effects (Shastry, 2005).   
 
In order to achieve high drug bioavailability at specific target sites, there has been 
a shift in the drug development arena towards focusing more on the systems 
governing drug delivery.  Researchers are investigating various DDS to enhance 
the bioavailability of drugs and to decrease the occurrence of unwanted side 
effects by more accurately depositing drugs directly to the target sites. 
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1.2 Current drug delivery routes 
The methods of drug delivery most frequently used in the clinic include enteral and 
parenteral systems.  Enteral drug delivery includes oral and sublingual 
administration of drugs.  In oral delivery a drug is given by the mouth and ingested 
as opposed to sublingual administration where a drug is placed beneath the 
tongue and allowed to diffuse into the capillary network and subsequently enter 
the systemic circulation directly (Thanou et al., 2001). 
 
Oral administration is the most preferred route as it is painless and self-
administered (Plapied et al., 2011).  Orally administered drugs are normally 
absorbed into the blood stream via passive intracellular diffusion where the 
intestinal epithelium provides a physical barrier to the absorption of drugs.  This in 
turn presents a challenge to the absorption of drugs by the circulatory system 
(Plapied et al., 2011).  Furthermore, chemical and enzymatic fluids in the GIT 
contribute to drug degradation which prohibits the administration of 
macromolecules (Plapied et al., 2011).  Another disadvantage of oral drug 
administration is the time required for the drug to travel through the intestine as it 
can result in incomplete drug release which then leads to a diminished efficacy of 
the administered dosage (Singh et al., 2000).   
 
Additional routes of administration are parenteral which involve the use of a 
needle, injection or catheter to introduce drugs directly across the body’s barrier 
defences into the systemic circulation.  This route allows for the delivery of drugs 
that are poorly absorbed or unstable in the GIT (Kumar et al., 2007).  
Administration of drugs using this method is painful, generates dangerous medical 
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waste and may cause an increased risk of infection at the injection site (Prausnitz 
et al., 2008).   
 
Transdermal drug delivery employs a patch which applies the drugs into the 
circulatory system through the skin (Kumar et al., 2007).  The method is non-
invasive, easy to self-medicate and the drug is not exposed to the harsh 
environment of the GIT (Naik et al., 2000).  Transdermal patches are however not 
able to deliver macromolecules with molecular weights greater than 1000 Da (Naik 
et al., 2000a).     
    
Although the above DDSs are the most widely used they have various limitations 
as they are designed to disseminate the drug into the body through the circulatory 
system (McAllister et al., 2003).  The drugs are subsequently able to interfere with 
body systems that are not infected or diseased leading to unwanted side effects 
where harmful and unpleasant reactions occur in the body as drugs accumulate in 
unaffected tissues and organs (Vasir et al., 2005).  This also results in the 
dosages being administered not reaching the sites of infection in concentrations 
that lead to effective efficacy levels (Torchilin, 2000).  To mitigate the host of 
limitations presented by these delivery systems, researchers have put much focus 
into the development of new DDSs with the ability to deliver exogenous and 
therapeutic agents to target sites in relevant therapeutic concentrations (Allen et 
al., 2004).  The applicability of DDS to move drugs across a membrane are first 
investigated at an in vitro level after which respective pre-clinical animal studies 
are carried out (Illum, 2003, Illum et al., 1994, He et al., 1998).  There are a variety 
of methods that have been explored for targeted delivery of therapeutic drugs and 
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genetic materials into mammalian cells at an in vitro level, and some of these 
methods are discussed in more detail below.  
 
1.3 Methods to deliver therapeutic agents in vitro 
The progression and development of therapeutic agents relies on the ability of 
these agents to penetrate the cell membrane.  Over the years a variety of methods 
such as electropermeabilization (Lundkvist et al., 2003), biodegradable 
nanoparticles (Panyam et al., 2003), cell-penetrating proteins and peptides (Gupta 
et al., 2005), folate mediated delivery (Lu et al., 2012), protein transduction (van 
den Berg et al., 2011), ultrasonic magnetic nanoparticles by magnetic resonance 
monitoring (Liu et al., 2010) and the use of theranostics with spatiotemporal 
imaging Knipe et al., 2013) have been utilized to achieve intracellular delivery of 
therapeutic agents.  Additionally, and briefly highlighted below is the use of 
chemical agents, physical methods, viral vectors, and nanoparticles.  
 
1.3.1 Delivery of nucleic acids by chemical methods 
Chemical methods of delivery, particularly during transfection procedures, have 
been utilized extensively in various studies as they are easy, versatile and have 
proved effective in the delivery of nucleic acids (Marivin et al., 2015).  Examples of 
chemicals usually used are calcium phosphate (Jordan et al., 1996, Jordan et al., 
2004), 2-(diethylamino)ether (DEAE)-dextran (Mack et al., 1998), artificial lipids 
(Zhi et al., 2010, Shiraishi et al., 2012) and proteins to name a few.  With all its 
advantages, chemical transfections may be limited by their toxic effects as well as 
a difficulty to adapt to in vivo studies (Luo et al., 2000).   
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1.3.2 Physical methods 
1.3.2.1 Electroporation  
Electroporation uses short and intense electric pulses to increase the permeability 
of the lipid bilayer of mammalian cells (Gehl et al., 1999), ultimately creating 
hydrophilic pores and temporary damage to the membrane (Wang, 2013).  The 
generated pores allow passage of non-permeating molecules to enter into the 
cytosol via diffusion (Pucihar et al., 2008).  Electroporation has been used in 
delivering various macromolecules such as proteins and nucleic acids both in vitro 
and in vivo (Choi, 2012).  Examples of in vivo studies include the transfer of 
plasmid DNA and siRNA into dental tissues of rats (Yao et. al., 2014) and in the 
study of nucleic acid transfer into rodent brains in turn facilitating an understanding 
of brain disorders in gene therapeutics studies (Ding et. al., 2014).  However, the 
high mortality of cells after exposure to high voltages renders electroporation 
unfavourable as it leads to tissue damage (Luo et al., 2000).  Additionally, during 
in vivo electric field application, pain and muscle twitching in large animals and 
humans have been reported and attributed to nerve stimulation (Tjelle et al., 
2006).    
 
1.3.2.2 Particle bombardment 
Particle bombardment or biolistics is a method where exogenous materials are 
coated into heavy metal particles (tungsten or gold) (Davis et al., 1999).  The 
micron-size metal particles are loaded into a macrocarrier where a gas, most 
commonly helium (He), is applied with high pressure causing the macrocarrier to 
be propelled forward and upon sudden stopping the microparticles are projected 
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by the principle of inertia into the target cells (Zilony et al., 2013, Klein et al., 
1987).     
 
The transfection efficiency of treated cell populations is determined by particle size 
and target distance (Tanner et al., 1997).  Biolistics have been used in a variety of 
studies involving transfection of genes into plant cells (Klein et al., 1987), gene 
silencing (Shefi et al., 2006), in vitro delivery of cancer therapeutics (Zilony et al., 
2013), and expression of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) 
in parasitic helminths (Davis et al., 1999).  Biolistics has however been reported to 
have limited accuracy and reproducibility (Shefi et al., 2006).   
 
1.3.2.3 Microinjection 
Microinjection is a physical method where a glass needle (such as a microcapillary 
pipette or injection) is employed to directly inject exogenous materials into the 
nucleus or cytoplasm of the cell with high efficiency (Nelson et al., 2002), through 
hydrostatic pressure (Mehier-Humbert et al., 2005). 
    
Microinjection allows single cells to be micromanipulated one at a time which 
proved advantageous in various studies where the manipulation of neuronal cells 
was carried out (Lappe-Siefke et al., 2008, Wong et al., 2014, Guo et al., 2010).  
The single cell treatment aspect of microinjection has also been shown to enhance 
the development of mouse models for the investigation of disease mechanisms 
and the production of therapeutic agents; for example, (Wefers et al., 2013) 
Page 10 of 152 
 
successfully microinjected transcription activator like effector nucleases into 
single-cell embryos.  
 
1.3.3 Viral methods 
Viral mediated gene delivery is the most efficient method of intracellular delivery, 
where adenoviruses and lentiviruses are the most commonly used viral vectors 
(Sugiyama et al., 2005).  An optimal viral vector is one which is able to transduce 
into both dividing and nondividing cells.  The transduced cell must consequently 
have the ability to produce sufficient quantities of the inserted target gene 
(Sugiyama et al., 2005).  Both adenoviruses and retroviruses are able to infect 
dividing and nondividing cells  but adenoviruses do not allow for integration into 
the host cell genome while retroviruses are incorporated stably into host genome 
resulting in prolonged gene expression (Sugiyama et al., 2005, Price et al., 1987).   
 
While viral mediated delivery may be efficient for gene delivery (An et al., 2003) it 
may present un-wanted immune responses in immunocompetent animals and 
humans.  For example, great promise in the correction of haemophilia B using an 
adenovirus-associated virus (AAV) was demonstrated in a clinical setting however, 
unwanted cytotoxic T-lymphocyte responses against the transduced hepatocytes 
were still observed (Manno et al., 2006, Mingozzi et al., 2007).  In a later study, no 
acute or long-lasting toxicities were observed in severe haemophilia B patients 
where an enhanced AAV version was used.  However, elevated levels of 
aminotransferases induced by the AAV-capsids mediated an immune response 
especially when higher prophylactic injections were administered (Nathwani et al., 
2011).   
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1.3.4 Nanoparticles as a drug delivery system 
Nanoparticles (particles with sizes ranging from 1-100 nanometers)  have been 
reported to hold great potential in overcoming physiological barriers and guide 
therapeutic drugs to specific cells either by passive or ligand-mediated or active 
targeting mechanisms (Mallipeddi et al., 2010).  Passive targeting, which requires 
that the nanoparticles circulate continuously in the blood stream to ensure that 
they are exposed to the target site, is a mechanism which takes place as 
nanoparticles encounter extravasation at the target site.  This presents a challenge 
as the half-lives of nanoparticles may be relatively short due to host natural 
defence mechanisms which eliminate them from the body (Koo et al., 2005).  This 
challenge can be dealt with by ligand-mediated active targeting where a target 
ligand such as an antibody (Kim et al., 2009), bacteriophage (Li et al., 2011) or 
ARV drugs (Govender et al., 2008) drugs is included in the nanoparticle.  Active 
targeting therefore allows the ligand to bind to a specific cell-surface antigen 
and/or reporter in the target site (Cho et al., 2008). 
 
Nanoparticles are classified into various groups based on the material used during 
manufacturing, such as liposomes (Al-Jamal et al., 2011), dendrimers (Kesharwani 
et al., 2014), polymeric nanoparticles (Ensign et al., 2012), solid lipid nanoparticles 
(Kakkar et al., 2011) and metal nanoparticles (Kumar et al., 2011, Rasmussen et 
al., 2010).   
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1.3.5 Laser assisted transfection 
First demonstrated in 1984, a laser based method to introduce exogenous genetic 
materials into mammalian cells was developed (Tsukakoshi et al., 1984).  This 
technique employs either continuous wave (CW) or pulsed laser sources of 
different wavelengths to deliver exogenous matter into mammalian cells (Palumbo 
et al., 1996, Paterson et al., 2005). To achieve this, a tightly focused laser beam 
spot is tailored and employed to generate a high precision “self-healing” pore on 
the cell plasma membrane (photoporation).  Through the generated pore, 
exogenous materials contained in the medium to which the cells are submerged 
are taken up (Tsukakoshi et al., 1984).  Laser assisted delivery of exogenous 
materials into cells, which is the focus of this dissertation, is discussed in more 
detail in section 1.6. 
 
1.4 A brief introduction to lasers 
A laser is a device which emits directional, coherent and monochromatic light 
commonly referred to as a laser beam.  The term LASER is an acronym which 
stands for Light Amplification by Stimulated Emission for Radiation.  As suggested 
by the term, the action of a laser is governed by the process of stimulated 
emission.  A laser is composed of a lasing material (crystal, gas, dye, etc), a pump 
source which adds energy to the lasing material (flash lamp, electrical current, etc) 
and an optical cavity.  The optical cavity consists of a totally reflective mirror and a 
partially reflective mirror (Figure 1.1) (Milonni et al., 2010). 
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Figure 1.1: Schematic representation of basic laser components and operation. 
 
In the lasing material are atoms to which electrons are contained.  Electrons are 
normally in a steady state lower energy level.  Energy is added to the active 
medium resulting in the excitation of electrons to a higher energy state.  Here the 
electrons are in an unstable state and will stay at this energy level for a brief 
period of time.  The electrons therefore decay back to their original energy state in 
one of two ways, either by spontaneous decay or by stimulated decay (Milonni et 
al., 2010).  A diagram depicting spontaneous and stimulated decay is shown in 
Figure 1.2.  
Page 14 of 152 
 
 
Figure 1.2: Three level laser energy showing spontaneous and stimulated decay.   
Qe, excited energy level; Qm, metastable energy level; Q0, ground energy level; e-, electron.  
 
During spontaneous decay the electrons fall to the ground state while randomly 
directed photons are emitted.  In stimulated decay, photons from spontaneously 
decaying electrons strike excited electrons causing them to fall to the ground state.  
Energy is released in the form of photons of light which travel in phase at the same 
wavelength and in the same direction as the incident photon.  In a case where the 
direction of the photons is parallel to the optical axis, the emitted photons travel 
back and forth in the optical cavity through the lasing material as depicted in 
Figure 1.1.  The lasing material is situated in between a totally reflective mirror and 
a partially reflective mirror (Milonni et al., 2010).   
 
 
 
Lasers can either operate in a continuous wave (CW) mode where the power 
output remains the same irrespective of time or in a pulsed manner.  By contrast, 
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pulsed lasers operate such that the power varies with respect to time at a 
repetitive rate as shown in Figure 1.3 (Lackner, 2008). 
 
Figure 1.3: Continuous wave (CW) and pulsed modes of laser operation.   
CW power levels (in watts) remain constant over time (in seconds; blue) whilst pulsed laser modes (red) 
experience varying power levels with respect to time.  
 
The output power of pulsed lasers is stored in the power supply of the laser where 
the stored energy is capable of reaching very high levels.  High-intensity laser 
pulses result from a discharge of the stored energy into the laser whilst the peak 
power levels of the pulses exceed the power levels attainable with a CW laser 
beam (Al-Watban et al., 2004). 
 
 
1.5 Brief overview to Gaussian beams 
A variety of lasers exist with different characteristics and specifications, allowing 
different lasers to be used for different functions.  This section of this dissertation 
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therefore gives a brief background on the propagation of lasers with a Gaussian 
profile so as to bring to light the functionality of the laser used in this study. 
 
1.5.1 Gaussian beam propagation 
Although lasers propagate in a coherent manner, in reality they diverge slightly as 
they propagate by an angle theta ( , see Figure 1.4) away from the beam waist, 
ω0.  Angle   which describes the angular spread (divergence) from the beam 
diameter (2ω0) is given by: 
0

            (1.1) 
 
where  is the wavelength of the laser light (Saleh et al., 1991).  The Rayleigh 
range, 
RZ  of a Gaussian beam refers to the distance from the ω0 where the radius 
is increased by a factor of 2 .  The 
RZ  is essentially the standard length used to 
measure the divergence of the beam and is depicted as: 

 20RZ .          (1.2) 
 
Both the divergence angle and the Rayleigh range are depicted in Figure 1.4. 
 
Figure 1.4: Gaussian beam propagation in the 
RZ 
direction.   
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The Gaussian beam width  z changes as a function of distance along the beam.  0 : Beam waist; b : 
depth of focus; 
RZ : Rayleigh range; Θ: total angular spread. 
 
The beam depth of focus,b , refers to the axial distance where the beam radius lies 
within a factor 2  of its minimum value.  The beam has its minimum width at a 
propagation distance of 0z  so the best focus of the laser is at the plane 0z .  
On either sides of this position the beam gradually goes out of focus and the beam 
waist subsequently increases away from this position (Saleh et al., 1991). 
 
1.5.2 Gaussian beam Intensity 
The intensity of any laser is given by     2rErI   and is a function of the axial and 
radial distances z  and r  respectively where r  is given as: 
       2
1
22 yxr  .         (1.3) 
 
The intensity of a Gaussian beam can then be expressed as: 
 
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        (1.4) 
 
where the peak intensity is .
2
00 EI    The Gaussian function has its peak at 0r  
and decreases monotonically as r  increases.  A Gaussian beam has its greatest 
intensity at the position of the beam waist where the peak intensity is at the centre 
of the beam  0,0  zr .  The intensity profile of a Gaussian beam is shown in 
Figure 1.5. 
Page 18 of 152 
 
 
Figure 1.5: Intensity profile of a Gaussian beam. 
 
1.6 Application of lasers to delivering therapeutics in biomedical research 
Various types of laser sources have been used in the biomedical research arena 
for successful introduction of exogenous agents in in vitro transfections.   When 
first demonstrated, Tsukakoshi et al., (1984) used a nanosecond (ns), pulsed laser 
in the ultraviolet (UV) region of the electromagnetic (EM) spectrum (Tsukakoshi et 
al., 1984).  Since then, utilized laser sources have varied from CW lasers within 
the visible range of the EM spectrum (Palumbo et al., 1996, Schneckenburger et 
al., 2002, Paterson et al., 2005) to pulsed laser sources in the near-infrared (NIR) 
spectral region (Tirlapur et al., 2002, Stevenson et al., 2006, Uchugonova et al., 
2008).  The mechanism of CW laser based photo-transfection is based on single 
photon absorption and photochemical effects (Schneckenburger et al., 2002).  The 
highest transfection efficiencies obtained through this mechanism are in the range 
of 30% (Schneckenburger et al., 2002) however, due to the high irradiance 
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thresholds required for CW membrane permeabilisation, ablative effects and 
subsequent cell damage follows laser irradiation. 
 
In the case of pulsed laser sources, the delivery of exogenous materials into the 
cells has been achieved using ns, picosecond (ps) and femtosecond (fs) pulse 
durations.  Nanosecond pulses have been utilised in various studies, as 
mentioned earlier when the technique was first introduced by (Tsukakoshi et al., 
1984), a laser with a 5 ns pulse duration was employed.  In a study by 
Venugopalan et al., (2002), ns lasers at 532 and 1064 nm were employed to 
investigate the physical processes involved in cell micromanipulation where water 
was employed to investigate the respective physical mechanisms.  This follows 
results reported by Docchio et al., (1986) where it was shown that in water, ocular 
and other biological media, the optical breakdown threshold is similar.  The results 
of the study by Venugopalan et al., (2002) indicated that harmful effects such as 
cavitation bubbles and shock wave dynamics were associated with the use of ns 
laser pulse durations.  From this study it was deduced that employing laser 
sources with shorter durations would be advantageous as optical breakdown is 
understood to decrease with decreasing pulse durations (Venugopalan et al., 
2002).  Picosecond pulses which lie in between ns and fs pulse durations also 
induce harmful effects in cells but at a milder level than that observed in the case 
of ns pulses.   
 
First demonstrated by Tirlapur et al., (2002), fs laser sources in the NIR spectral 
region have become the most understood and most commonly utilised laser 
source for photoporation and photo-transfection.  In their study, Tirlapur et al., 
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(2002) reported being able to achieve transfection efficiencies of 100% 
irrespective of which cell line they used for their experiments.  Furthermore they 
reported that no harmful effects were detected within the treated cell populations.  
Compared to the ns laser used by Tsukakoshi et al., (1984), Tirlapur et al., (2002) 
used a fs pulsed titanium sapphire laser with a repetition rate of 80 MHz and a 
wavelength of 800 nm.  Here the viability of the transfected Chinese hamster ovary 
(CHO-K1) and the rat-kangaroo kidney epithelial (PtK2) cells remained intact.  
This comparison between the two laser modes used in these studies was further 
investigated by Zeigler et al., (2009) when they showed that using a ns pulsed 
laser source at the UV spectral region (337 nm) yielded a 36% cell viability in NG-
108 (neuroblastoma glioma) cells as opposed to a 79% viability when a fs pulsed 
laser source in the NIR spectral region (770 nm) was used for the transfection 
experiments.    
 
Femtosecond laser sources in the NIR spectral region have been demonstrated 
where fluorescent plasmids were delivered into a variety of cell lines such as HeLa 
(Henrietta Lacks) (Niioka et al., 2008), HEK (human embryonic kidney) (Mthunzi et 
al., 2010), CHO (Tirlapur et al., 2002) as well as in stem (Uchugonova et al., 2008) 
and neuronal cells (Barrett et al., 2006), of which the latter cells have both been 
reported as difficult cells to transfect.  Photoporation has shown successful 
delivery of fluorescent markers Lucifer yellow (Mallipeddi et al., 2010), green 
fluorescence protein (GFP) (Mthunzi et al., 2010) and the transcription factor Elk1 
messenger RNA (mRNA) (Barrett et al., 2006).  Photoporation is a selective 
method as it allows targeted treatment of individual cells in a population 
(Stevenson et al., 2010).  The technique has also shown sub-cellular accuracy 
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where different regions of cells can be targeted preferentially (Barrett et al., 2006).  
In addition to the fact that fs laser assisted delivery of exogenous material offers 
higher transfection efficiencies than conventional methods (e.g. 100% (Tirlapur et 
al., 2002) versus 30% for chemical transfections), the technique is advantageous 
over the other methods that have been discussed thus far as it offers reproducible 
results and no direct physical contact with the cell takes place.  
 
Although great strides have been made towards the development of DDS, major 
drawbacks are their applicability in the clinical setting.  In a study by Zeira et al., 
(2003), energy pulses from a fs titanium sapphire NIR laser were used to deliver 
plasmids expressing a murine erythropoietin gene into the tibial muscle of mice.  
Following DNA injection, cells beneath the skin were illuminated by the laser 
resulting in gentle cell poration.  This led to high murine erythropoietin expression 
with negligible tissue damage in the mice (Zeira et al., 2003).  Following that study, 
Zeira et al., (2007) further modified the fs laser delivery system reported in 2003 
such that it included an articulated arm.  This modification allowed for precise 
guided targeting of the laser to desired sites of injection (Zeira et al., 2007).  The 
collaboration of lasers and an articulated arm has also been shown to be effective 
for in vivo use (Chen et al., 2012).  Here the articulated arm was employed to 
optically translocate a hydrophilic model drug sulforhodamine B, methyl blue and a 
model vaccine antigen ovalbumin into male BALB/c mice models (Chen et al., 
2012).  With their ability to be precisely focused to the site of injection together 
with the flexibility of the arm, the technology has potential for gene and drug 
delivery into larger animals as well as humans (Zeira et al., 2007).  A further 
advantage of laser technologies is that they can be integrated with surgical or 
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medical devices like endoscopes to reach areas that are non-approachable 
treatment sites during medical operations or interventions in the clinic (Menezes et 
al., 2012).  There is no literature on the use of fs photo-poration to assist in the 
delivery of drugs into mammalian cells. 
 
1.7 Mechanisms of fs photoporation 
It is essential to understand the physical principals which govern fs photoporation 
in order to achieve usefulness of the technique and increased efficiencies during 
experiments.   
 
1.7.1 Laser induced optical breakdown 
Laser induced optical breakdown refers to the formation of a plasma in transparent 
media such as water or biological materials such as cells (Docchio et al., 1988).  A 
plasma is generated in transparent biological media through the formation of 
quasi-free electrons as a result of an interplay of multiphoton and cascade 
ionization when high intensity laser pulses are focused onto the transparent 
medium (Noack et al., 1998).  A diagram showing the generation of a plasma 
through laser induced breakdown is depicted in Figure 1.6. 
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Figure 1.6: Plasma formation through the interplay of multiphoton and cascade ionization.   
Repeat cycles of inverse Bremsstrahlung absorption and impact ionization result in the avalanche growth of 
the number of free electrons. t: time, E: energy, Ecrit: critical energy, Egap: band gap energy, Eosc: oscillation 
energy and Δ: excitation energy (Redrawn from (Vogel et al., 2005)).  
 
A free electron produced in the active medium absorbs photons in a process 
known as inverse Bremsstrahlung absorption which refers to the mechanisms 
involved in the transfer of energy from laser light in matter (Schlessinger et al., 
1979).  As the photons are being absorbed the electron gains kinetic energy.  
Absorption by inverse Bremsstrahlung takes place several times after which the 
gained kinetic energy is large enough to produce another free electron through 
impact ionization.  As a result, two free electrons with slow movement (low kinetic 
energy) become available.  Repetitive cycles of inverse Bremsstrahlung 
absorption and impact ionization take place and result in the avalanche growth of 
free electrons (Rudd et al., 1992).  It is important to note that the electrons will also 
collide with heavy charged particles such as ions and atoms at which time a 
fraction of energy is lost (Rudd et al., 1992).  For the avalanche growth in the 
number of electrons to take place, the irradiance must be high enough to 
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overcome the losses in free electrons which may have been experienced through 
the diffusion of electrons from the focal volume (Stuart et al., 1996).  Also, the 
energy gained through inverse Bremsstrahlung must be rapid compared to that 
lost during collisions with heavy particles.  This whole process is referred to as 
avalanche ionization or cascade ionization (Vogel et al., 2005). 
 
1.8 Mechanisms for laser effects on biological cells and tissues  
Femtosecond laser induced cell permeabilization research has come a long way in 
understanding the mechanisms involved in the functionality of the technique.  The 
majority of the studies that have been reported (Mthunzi et al., 2010, Tirlapur et 
al., 2002, Uchugonova et al., 2008, Zeira et al., 2003) have made use of lasers 
with high laser oscillation repetition rates in the range of 80 MHz and pulse 
energies below the optical breakdown threshold (Vogel et al., 2005).  This 
however only accounts for one of the treatment regimens available for 
photoporation.  The other employs laser oscillators which emit low repetition rates 
of 1-kHz.  These are not commonly used in studies due to the fact that they result 
in bubble formation as they are slightly above the optical breakdown threshold 
(Vogel et al., 2005). 
 
Using the 80 MHz regime, 40 000 to several million pulses have been utilised at 
one spot of the cell membrane to induce permeability (Koenig et al., 2002).  On the 
other hand, 30 to several hundred pulses have been used for the same purpose 
using 1-kHz repetition rates (Heisterkamp et al., 2005, Maxwell et al., 2005).  
Using low repetition rate oscillators, cavitation bubbles which are known to induce 
damage on the cell’s integrity have been reported.  In Figure 1.7 below an 
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overview of experimental damage, transfection and dissection thresholds on 
biological cells is shown.  These are shown in conjunction with different low-
density plasma effects and physical breakdown phenomena (Vogel et al., 2005).   
 
Figure 1.7: Summary of physical breakdown phenomena on biological cells as induced by fs laser pulses. 
The different effects are shown alongside corresponding values of free electron densities and irradiances 
where the values are normalised to the optical breakdown threshold Ith.  Ith is defined by a critical electron 
density of Qcr=10
21
 cm
-3
.  Copied from
 
(Vogel et al., 2005).  
 
Overall, where the choice of which type of laser source is optimal to achieve 
enhanced permeability of biological cells with the aim to enable cells to take up 
exogenous materials is in question, fs pulsed laser sources take precedence over 
ns, ps and CW laser sources.  Also, repetition rates of 80 MHz are preferred over 
1-kHz as they do not often result in negative effects such as bubble formation.  
The photochemical effects induced by fs lasers through the generation of free 
electrons are spatially confined to precisely the exposed spot on the cell 
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membrane.  Furthermore, the energy levels required to achieve cell ablation are 
very low thereby shielding the cells from detrimental effects such as cavitation 
bubbles and shockwaves which are kept to an absolute minimum in the case of fs 
laser sources at high repetition rates.  
 
1.9 Photo-translocation of drugs 
Femtosecond photoporation is a high precision technique whose applicability to 
various cell lines to deliver various exogenous materials is discussed in section 
1.6.  The concept of the technique is described in section 1.3.5.  To date, the laser 
based technique discussed here has not yet been used to deliver drugs into target 
cells (photo-translocation).  Since the use of current DDS lead to unwanted side 
effects as drugs are able to accumulate in unaffected tissues and organs, a DDS 
involving the use of a laser is an attractive alternative to the safe delivery of drugs 
directly into target sites. 
 
1.10 Photo-translocation: It’s application to the clinical setting 
Although demonstrated at a cellular and in vitro level, photo-translocation of drugs 
would also be suited in vivo for drug delivery into tissues, organs, bones and 
muscles.  This technology has applicability in assisting with the delivery of 
therapeutic agents of various diseases including but not limited to non-
communicable diseases such as cancer and cardiovascular diseases as well as 
communicable diseases such as Mycobacterium tuberculosis (TB), human 
immunodeficiency virus type 1 (HIV-1) and the Ebola virus.  The technology could 
also be used in targeting difficult to reach areas where drug penetration is limited 
by the presence of physiological barriers (such as the blood brain barrier (BBB)). 
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The application of laser sources to the delivery of exogenous material such as 
fluorescent plasmids has been demonstrated in vitro by various studies (Mthunzi 
et al., 2010, Tirlapur et al., 2002, Uchugonova et al., 2008, Zeira et al., 2003) and 
the potential of lasers as a DDS to reach the clinical setting has been one of the 
major concerns of this technology.  In a patent, US Pat No 5 925 012 issued on 
July 20, 1999 to Murphy-Chutorian, they showed that they developed an 
apparatus with the ability to dispense predetermined amounts of therapeutic 
agents into target areas of the human body.  The application of the apparatus is 
disclosed in the patent where the apparatus is described in detail.  The 
administration of the drug is suggested to be possible through administration in an 
opening (such as a cut) in the human body.  The described apparatus consists of 
a laser inlet and a drug inlet.  The laser inlet is used to guide a means to deliver 
the laser light such as an optical fibre to the target body structure where an 
opening will be generated.  The drug inlet is designed to receive and transmit the 
drug to the created opening.  Daniel et al., (1999) describes that the administration 
of the drug would be by manual or automated actuation of a piston or syringe 
element.  Although these studies were done to demonstrate the use of a laser as a 
DDS, the application of the apparatus to deliver the drugs in vitro and in vivo have 
not yet been demonstrated.   
 
By using such an apparatus and incorporating an articulated arm for better 
direction as well as a camera as in the case of endoscopy as suggested by Zeira 
et al., (2007) the administration of drugs in a localised manner may be achievable 
in the clinical setting.  A DDS of this nature would allow drug administration into 
tissues thus minimizing the amount of drug required, minimizing dosing periods 
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and in turn decreasing the costs of treatments.  Confining administration of 
therapeutics to defined target locations of the body would also enable otherwise 
toxic drugs to be delivered in a controlled manner.   
    
1.11 Photo-translocation: It’s application to intracellular infections 
Intracellular infections such as mycobacterial infections, malaria and HIV-1 are 
some examples where the antimicrobial treatment requires delivery of drugs 
directly into infected cells, tissues or organs (Briones et al., 2008).  For the 
purposes of this proof-of-principle study we will only focus on HIV-1 infection. 
 
In this study, the use of lasers is employed to assess whether antiretroviral (ARV) 
drugs which already exist in the pharmaceutical market for treating HIV-1 can be 
more efficiently delivered into target cells by photo-translocation.  Photo-
translocation is therefore defined as a laser based technique that utilizes laser light 
sources as a means to facilitate or improve on the intracellular delivery of 
exogenous materials such as ARV drugs (Figure 1.8).   
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Figure 1.8: Schematic representation of a sample chamber with adherent HIV-1 permissive cells in an ARV 
drug and growth medium solution.   
A focused laser is shown during the process of cell membrane poration where subsequent diffusion of the 
ARV drug through the generated pore takes place. 
  
Additional advantages making laser based techniques desirable for drug delivery 
are that the technique can be coupled with various optical techniques such as 
microscopy (Stevenson et al., 2010) that permit real time viewing of in vitro drug 
delivery studies. 
 
1.11.1 Epidemiology of HIV-1 
HIV-1, the causative agent for acquired immunodeficiency syndrome (AIDS) 
infects clusters of differentiation 4 positive (CD4+) T lymphocytes of the human 
immune system (Ratner et al., 1985, Barre-Sinoussi et al., 1983).  By depleting 
CD4+ T lymphocytes the virus progressively reduces the effectiveness of the 
immune system leaving infected individuals susceptible to opportunistic infections 
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and tumors, ultimately leading to death (Klatzmann et al., 1984, Lifson et al., 
1986).   
 
1.11.2 HIV-1 life cycle and potential ARV drug targets    
Several steps in the HIV-1 replication cycle are potential targets for therapeutic 
interventions.  The first step of the cycle is the attachment of the virus using 
surface envelope (env) glycoprotein, gp120, to the host cell surface receptor 
(CD4) (Maddon et al., 1986).  This step is followed by a conformational change in 
env which enables gp120 to bind to a cellular chemokine co-receptor (C-X-C motif 
receptor type 4 (CXCR4) or C-C chemokine receptor type 5 (CCR5)) (Alkhatib et 
al., 1996).   The env glycoprotein gp41 then interacts with the host cell plasma 
membrane which results in the fusion of the membranes of the virus and the host 
cell (Kowalski et al., 1987, Eckert et al., 2001).  Currently United States (US) Food 
and Drug Administration (FDA) approved entry inhibitors bind to either env 
proteins or to chemokine coreceptors to prevent the virus from entering the cell 
(Este et al., 2007).   
 
Following fusion, the conical shaped viral core (p24) is deposited into the host 
cell’s cytoplasm.  The viral core contains two copies of single stranded RNA, viral 
proteins and primer transporter RNA (tRNA) (Ganser et al., 1999).  The viral core 
is then uncoated to enable the viral genetic material to be reverse transcribed into 
cDNA by the reverse transcriptase (RT) enzyme (Bukrinsky et al., 1993).  
Nucleoside reverse transcriptase inhibitors (NRTIs) can inhibit this step by being 
preferentially incorporated into viral DNA to act as chain terminators (Furman et 
al., 1988).  Non-nucleoside RTIs (NNRTIs) are also able to inhibit this conversion 
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by directly binding to RT.  The newly synthesized viral DNA binds to HIV-1 
integrase, and a range of other viral and host proteins to form of a pre-integration 
complex (PIC) which is then translocated into the nucleus of the host cell 
(Bowerman et al., 1989).  The viral DNA is irreversibly inserted into the host’s 
genome by viral integrase, and the integration process is completed by the host 
DNA repair elements to form a provirus (Goff, 1992, Bowerman et al., 1989).  
Strand transfer integrase inhibitors prevent the integration process in the nucleus.  
The provirus then follows one if two possible routes.  It can either be transcribed to 
ultimately form new progeny virions or can lie dormant in a state of latency 
(Siliciano et al., 2004).  Viral proteins are transcribed, and a range of viral mRNA’s 
(singly, multiply spliced and unspliced) are translated in the cytoplasm to generate 
all the necessary viral proteins.  The envelope glycoproteins (gp160) is cleaved by 
cellular proteases into gp120 and gp41 components, and the gag-pol polyprotein 
is cleaved by the viral protease enzyme (Sodroski et al., 1986).  
  
The final steps of the HIV-1 life cycle are viral assembly, budding and maturation.  
Assembly involves the packaging and creation of the virus where HIV proteins are 
recruited to the cell membrane.  The budding process encompasses the immature 
virus budding out of the cell with the host plasma membrane components within 
which the viral envelope glycoproteins are embedded.  The final step which is 
maturation involves completion of the gag-pol polyprotein cleavage, which permits 
the virus to be able to infect subsequent cells.  HIV-1 protease is the enzyme 
responsible for the maturation process (Warnke et al., 2007).  Protease inhibitors 
prevent gag-pol polyprotein cleavage, resulting in immature, non-infectious virions. 
An illustration of the viral life cycle is shown in Figure 1.9.  
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Figure 1.9: Life cycle of HIV-1 and site of action of antiretroviral therapy (red text).   
Adapted from (Furtado et al., 1999).  
 
1.11.3 Current HIV-1 treatment 
The current treatment for HIV-1 infection, termed highly active antiretroviral 
therapy (HAART), involves the oral administration of a combination of a minimum 
of three US food and drug administration (FDA) approved ARV drugs. The drugs 
prevent progression of HIV-1 infection to AIDS by blocking or interfering with 
specific parts of the viral life cycle (Martinez et al., 2002a, Warnke et al., 2007).  
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FDA approved ARVs are grouped into four categories according to their 
mechanism of action, namely entry inhibitors (EI, e.g. maraviroc), RTIs (nucleoside 
RTIs (NRTI, e.g. tenofovir) and NNRTI (e.g. efavirenz)), integrase inhibitors (INs, 
e.g. raltegravir) and protease inhibitors (PI, e.g. ritonavir) (Arts, 2012). 
 
The introduction of HAART has over the years decreased AIDS related mortalities 
subsequently increasing the life expectancy of HIV-1 infected persons (Sharma et 
al., 2010). However, HAART faces challenges and limitations that are cause for 
concern. Once HAART is initiated, treatment is lifelong, which can result in 
toxicities, as well as the inevitable emergence of ARV drug resistance (Este et al., 
2010). Host genetics, which impact on plasma and intracellular concentrations of 
ARVs is an additional concern. Furthermore, since HAART cannot target the latent 
viral reservoirs there is currently no cure for HIV-1 infection (Katlama et al., 2013). 
ARV drugs possess a poor targeting ability to latent sites of infection including the 
CD4+ memory T cells, lymphatic system, macrophages, the central nervous 
system and the lungs (Sharma et al., 2010, Reviewed by Alexaki et al. (2008)).  
More specifically, in the lungs and brain HIV-1 is contained in alveolar 
macrophages and microglia respectively, to which the drugs are not able to 
penetrate (Von Briesen et al., 2000, Hu et al., 2000).  Since the existing US FDA 
approved ARV drugs are not able to eradicate latent virus, novel drugs and DDS 
to target this integrated provirus are required.    
 
Worldwide, there is a major drive to understand and try eradicate HIV-1 from the 
latent reservoirs, resulting in a “functional” cure or cure.  A DDS with the future 
ability to deliver therapeutic concentrations of novel ARV drugs which specifically 
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target integrated proviruses in latent sites in patients on HAART with undetectable 
viral loads presents a novel approach towards eradication of HIV-1. Viral 
reservoirs are established early in HIV-1 infection and they hinder sterilizing 
immunity while also hindering possibilities of curing the infection with the potent 
ARV drug regimens currently in use (Dahl et al., 2010, Shen et al., 2008).  
Following successful ARV therapy, virus levels in the plasma of many patients 
becomes undetectable.  The long term persistence of HIV-1 is due to the presence 
of cellular and anatomical reservoirs.  Of the known reservoirs the most alarming 
is that consisting of latently infected resting memory CD4+ T cells which carry 
integrated HIV-1 DNA (Pierson et al., 2000).  HIV-1 latency can be described as 
integrated provirus with no active transcription and therefore no replication 
(Kulkosky et al., 2002).  Since the existing US FDA approved ARV drugs are not 
able to eradicate latent virus, novel drugs to target this integrated provirus are 
required.  The majority of the latent virus is found in CD4+ T cells of the memory 
phenotype where the half-life is a long period of up to 44 months (Blankson et al., 
2002).   
 
1.11.3.1 HIV-1 disease progression 
The clinical course of HIV-1 infection is made up of three phases namely; acute 
primary infection, clinically asymptomatic infection and the symptomatic HIV-1 
infection, and progression to AIDS phase (Cohen et al., 2010). 
 
The acute primary infection phase which can last up to 6 months, until the patient 
seroconverts, and is when HIV-1 infection is established (Lyles et al., 2000).  This 
phase is characterised by a rise in viral levels in the plasma as the virus is allowed 
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to replicate uncontrollably (Clark et al., 1991) and allowed to spread to lymph 
nodes and then into the bloodstream.  Infected cells can be lysed or they can 
manifest into latent infection where macrophages and resting CD4+ T cells 
establish themselves as viral reservoirs (Zack et al., 1988).  Following a rise in 
viral levels an immune response is elicited by cytotoxic T lymphocytes (CTLs).  A 
decrease in the viral levels in the plasma is subsequently observed, reaching a set 
point (Ogg et al., 1998).  A graphical representation of HIV-1 disease progression 
to AIDS is shown in Figure 1.10. 
 
 
Figure 1.10: Graphical representation of HIV-1 disease progression  
HIV-1 disease progression as a relationship between the changing levels of the CD4
+
 T cell count (cells/µl) 
and the HIV RNA copies (per ml) in the plasma.  The blue line represents the CD4
+
 T cell count while the red 
line represents the HIV RNA copies/mL of plasma.  Obtained from 
http://en.wikipedia.org/wiki/HIV#mediaviewer/File:Hiv-timecourse_copy.svg (Access date: 10 September 
2014). 
 
The second phase is the asymptomatic phase where there is an absence of 
symptoms.  This period which can last for up to 10 years is characterised 
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maintenance of the viral load set point in the plasma (Iwami et al., 2008).  This 
decline in viral load is due to the innate and adaptive immune responses of the 
host where antibodies bind to viral particles or cause the elimination of infected 
cells (Stamatatos et al., 2009).  During this period infected cells are eliminated as 
T-lymphocytes which are specific to HIV-1 recognise the virus antigens that are 
presented on the surface of infected cells.  While this elimination process occurs 
the HIV-1 continues to replicate and counteract the effects of the host’s immune 
responses while establishing a stage of chronic systemic inflammations (Fauci, 
1993).  The final stages of the asymptomatic phase sees the infected persons 
undergo a slow but progressive loss of CD4+ T cells where the immune system is 
subsequently led to its detriment (McCune, 2001).  The CD4+ T cell depletion 
occurs predominantly in the GIT (Brenchley et al., 2004) and sees the architecture 
of the lymphoid tissue go through a destruction which renders it permeable to viral 
diffusion to surrounding CD4+ T cells.  In turn, the virus is allowed to spread within 
the local, regional and whole lymphoid environments ultimately leading to a 
speedier progression to AIDS (Brenchley et al., 2004, Mehandru et al., 2004). 
 
Symptomatic HIV-1 infection and progression to AIDS is the final phase of disease 
progression and is characterised by the weakening of the immune system.  This is 
caused by a further decline in CD4+ T cells to levels lower than 200 cells/µl in the 
blood.  Consequently the body is left susceptible to opportunistic infections 
(Brooks et al., 2009).  Some infections which are prevalent among AIDS patients 
and often display limited clinical infection in healthy individuals include Candida 
albicans, Pneumocystis carinii, Cryptosporidium parvum and Toxoplasma gondii 
(Kasper et al., 1998).  During this AIDS phase patients present with symptoms 
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such as a reduction in body weight, respiratory and GIT symptoms while anemia 
and lymphopenia are normally detected during this phase (Revicki et al., 1995, 
Lucas, 1990).  In the absence of treatment regimens, the Joint United Nations 
Programme for HIV/AIDS (UNAIDS) and the World Health Organisation (WHO) 
predict that a person infected with HIV-1 should live a period of approximately 11 
years before perishing from AIDS-related illnesses.     
 
During 2012 there were 2.1 million new infections with 35 million persons already 
infected with HIV-1 worldwide (UNAIDS, 2014).  South Africa (SA) currently has 
approximately 6.3 million HIV-1 infected individuals, of which over 2.4 million 
people are receiving HAART. In addition, there were approximately 370 000 new 
infections in 2012 (UNAIDS, 2014). The high numbers of South Africans that will 
require HAART for their lifetime highlights the severity of the problem.  The long 
term toxicities associated with ARV combination therapy and the substantial 
financial implications necessary to treat all the patients that will still need treatment 
for their lifetime calls for urgent and novel approaches to eradicate latent reservoir 
sites (Pierson et al., 2000).  ARV therapy is vital to the treatment of HIV-1 
however, in its present form it is not likely to eradicate HIV-1 from infected 
persons.  Novel strategies and approaches should therefore focus on eradicating 
latent reservoir sites following effective usage of ARV therapy as induction therapy 
to enable undetectable viral levels to be achieved in the plasma (Kulkosky et al., 
2002). 
 
  
Page 38 of 152 
 
There is currently a major search in the research community for the acquisition of 
a “functional cure” to eradicate HIV-1 from reservoir sites (Katlama et al., 2013).  
The major priority of the majority of the studies is the discovery of new molecules 
with the ability to work safely on their own or in conjunction with other drugs to 
reactivate viral transcription with high efficiency in latently infected cells (Katlama 
et al., 2013).  This is widely referred to as drug infestation.  Continuous rounds of 
activated viral infection would in this case be blocked by ARV therapy and the 
productively infected cells would subsequently be destroyed (Lewin et al., 2011, 
Shan et al., 2012). 
 
This dissertation reports on a proof-of-principle study where a fs laser based DDS 
is demonstrated by delivering selected ARV drugs into HIV-1 permissive cells.  
The currently available ARV drugs used for the treatment of HIV-1 are not able to 
eradicate integrated HIV-1 provirus from reservoir sites.  While studies to purge 
HIV-1 from these sites and other studies continuing to search for and discover 
novel drugs to target integrated HIV-1 provirus, this study focuses on exploring 
pulsed fs laser sources for their use as a DDS.  This study therefore aims to show 
that it is possible to facilitate the more efficient delivery of therapeutic drugs 
(ARVs) into target, TZM-bl cells without compromising their viability.  As discussed 
previously, the technology has been utilized to deliver impermeable fluorescent 
dyes but has not yet been applied to the delivery of drugs as demonstrated in this 
study. 
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1.12 Research objectives 
The overall aim of the study was to set up a photo-translocation system to test its 
applicability in selectively and non-invasively delivering ARV drugs into HIV-1 
permissive cells. 
 
This was achieved by the following objectives: 
1. To assemble and characterize a photo-translocation set up (in-house).  
2. To assess the ability of the in-house photo-translocation setup which 
contains a fs laser, to deliver ARV drugs into TZM-bl cells and inhibit viral 
replication.   
3. To assess the viability of TZM-bl cells post treatment with the laser as well 
as ARV drugs. 
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2. Materials and Methods 
2.1 Reagents used in this study 
2.1.1 Cell lines 
TZM-bl cells, also called JC57BL-13, were obtained from the National Institutes of 
Health (NIH) AIDS Research and Reference Program ((catalogue (cat.) no. 8129).  
TZM-bl cells are a HeLa derived, genetically engineered cell line which expresses 
endogenous CXCR4 and transgenic CD4 and CCR5 on their cell membrane.  The 
HIV-1 permissive cell line also contains Tat-responsive reporter genes for firefly 
luciferase (Luc) and Escherichia coli (E.coli) β-galactosidase under the control of 
an HIV-1 (LTR).  These cells are highly permissive to infection by various HIV-1 
strains including primary and molecularly cloned Env-pseudotyped viruses (Brass 
et al., 2008).  TZM-bl cells were used in the laser treatment and in vitro phenotypic 
inhibition assay experiments.  HEK 293T cells were available in our laboratory and 
used in transfection studies to generate pseudoviruses. 
 
2.1.2 Plasmids used for the generation of molecularly cloned env-
pseudoviruses 
In this study an Env-pseudotyped virus, ZM53, which was originally acquired from 
a Zambian, male patient in the acute or early stage of infection was used (Derdeyn 
et al., 2004).  The HIV-1 env expressing ZM53 plasmid (cat. no. 11313) and the 
HIV-1 backbone plasmid pSG3Δenv (cat. no. 11051) which contains a defective env 
gene were both obtained from the NIH AIDS Research and Reference Reagent 
Programme.  
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2.1.3 ARV drugs used in the study 
A NRTI (tenofovir, cat. no. 10199) and two NNRTIs, efavirenz (cat. no. 4624) and 
nevirapine (cat. no. 4666) were selected for use in this study and obtained from 
the NIH AIDS Research and Reference Reagent Programme. 
 
2.2  Mammalian cell culture 
Both TZM-bl and HEK 293T cells were cultured in a 37°C, 5% carbon dioxide and 
85% humidity incubator.  The cells were grown routinely in a T-75 vented top 
culture flask (NuncTM, The Scientific Group, SA).  Cells were grown in general 
medium (GM) containing Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma 
Aldrich, SA), 10% fetal bovine serum (FBS, Sigma Aldrich, SA) and supplemented 
with 1% penicillin-streptomycin (PEST, Sigma Aldrich, SA).  The cells were 
trypsinised routinely at 70-80% confluency and passage numbers were recorded 
accordingly on the culture flask.   
 
2.2.1 Passaging of HEK 293T and TZM-bl cells 
Upon reaching 70-80% confluency, which means that 70-80% of the bottom 
surface of a T75 tissue culture flask (Nunc, The Scientific Group, SA) was covered 
by the cell monolayer, the cells were passaged.  Working in sterile conditions in a 
70 % ethanol disinfected biosafety level 2 hood, the GM in the flask was aspirated.  
The cell monolayer was washed with pre-warmed 1 × phosphate buffered saline 
(PBS, Sigma Aldrich, SA) to remove residual FBS.  The monolayer was bathed in 
0.25 % trypsin EDTA (Sigma Aldrich, SA) and left to stand briefly.  The trypsin was 
aspirated and the flask of cells was incubated in normal cell growth conditions for 
less than 5 minutes to allow trypsinization and lifting of the cell monolayer.  The 
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cells were then resuspended in GM, quantified (as described in section 2.2.2 
below) and 1 × 106 cells returned to the flask (or transferred to a fresh flask) and 
topped up with an appropriate amount of GM. 
 
2.2.2 Quantification of mammalian cells using a haemocytometer 
Cells were resuspended in GM after the process of trypsinisation, and 10 µl cell 
suspension was diluted in 40 µl of trypan blue viability dye (Sigma Aldrich, SA) to 
make up a 5 times dilution.  After gentle mixing, 10 µl of the sample was loaded 
onto the counting chamber of a haemocytometer by capillary action.  The counting 
chamber of a haemocytometer is engraved with a laser-etched grid of 
perpendicular lines consisting of nine 1 × 1 mm squares.  The 0.1 nm depth of the 
chamber gives each square a defined volume.  As such, each of the squares 
contains a volume of 104 µl.  The area bounded by the lines and the depth of the 
counting chamber are known thus making it possible to count the number of cells 
in a specific volume. 
 
Using a light microscope and focusing onto the grid of the counting chamber, the 
number of white cells in the four corner quadrants of the grid were quantified.  The 
total number of cells in the four quadrants was averaged by dividing the sum by 
four.  This value was multiplied by the dilution factor (i.e. 5) and by 104.  The 
resultant value gave an approximation of the number of cells per ml which made it 
possible to seed the required number of cells in an experiment as required. 
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2.2.3 Generation of molecularly cloned env-pseudoviruses 
The pSG3Δenv and ZM53 plasmids were transformed into competent E.coli Top 10 
cells.  Due to the incomplete genome of Env-pseudotyped viruses they are 
generally incapable of generating infectious progeny virions.  The Env-
pseudotyped viruses are therefore said to be capable of only a single round of 
infection.  The original plasmids were isolated using the Qiagen Maxiprep kit 
(Invitrogen) according to the manufacturer’s instructions (see section 2.2.6 below). 
  
2.2.4 Preparation of competent E.coli Top 10 cells 
To introduce DNA into bacterial E.coli cells (transformation) which are not naturally 
transformable, the cells have to gain competency.  This process which is induced 
by chemical methods ultimately allows the E.coli bacterial cells to take up DNA.  
The chemical, calcium chloride (CaCl2, Sigma Aldrich, SA), alters the permeability 
of the cell membrane thereby allowing DNA to cross the cell membrane. 
 
Luria Bertani broth (LB, 5 ml, Sigma Aldrich, SA) medium (10 g/L bacto-tryptone, 5 
g/L yeast extract, 5 g/L sodium chloride in distilled water and autoclaved at 120°C 
for 25 minutes) was inoculated with E.coli Top 10 and grown overnight at 37°C in a 
shaking incubator set at 200 revolutions per minute (rpm).  The overnight culture 
(1 ml) was used to inoculate 100 ml of LB medium.  The culture was shaken in a 
37°C water bath until the cell density reached mid-log growth phase 
(approximately 5 × 107 cells/ml).  The growth rate of the culture was determined by 
removing 1 ml aliquots of culture at various intervals after which the optical density 
was read at a 550 nm wavelength using a spectrometer.  The culture was chilled 
on ice for 10 minutes and the cell suspension spun at 4000 g in a centrifuge for 5 
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minutes at 4°C.  The supernatant was discarded ensuring that the pellet was not 
dislodged.  The pellet was resuspended in 50 ml of the original culture that 
contained 60 ml of sterile CaCl2 and 15% glycerol.  The cell suspension was 
placed in an ice bath for 30 minutes and then centrifuged at 4000 g for 5 minutes 
at 4°C after which the supernatant was discarded.  The pellet was gently 
resuspended in 5 ml of sterile ice-cold CaCl2 using pre-chilled pipettes.  Aliquots of 
50 µl were prepared and the competent E.coli Top 10 cells were stored for long 
term usage at -80°C. 
 
2.2.5 Transformation of competent E.coli Top 10 cells 
Competent E.coli Top 10 cells were thawed and kept on ice throughout the 
duration of the experiment to ensure that loss of competency was minimised.  Env 
pseudotyped viral plasmid (1 µl, ZM53 and pSG3Δenv) was transferred to 
eppendorf tubes that contained 25 µl of thawed competent E.coli Top 10 cells.  A 
negative control was prepared by transferring 26 µl of the cells into a separate 
eppendorf tube.  The tubes were incubated on ice for 30 minutes.  Following that, 
the samples were heat shocked at 42°C for 45 seconds and immediately kept on 
ice for 2 minutes.  The temperature shift enabled the cells to take up the ligation 
mixture.  Super optimal broth (SOC, Sigma Aldrich, SA) medium (250 µl) was 
added to the cells and incubated at 37°C in a shaking incubator at 200 rpm for 30 
minutes.  An additional 1 ml of SOC was added to the cell mixture and 25 µl plated 
aseptically on LB agar (10 g/L bacto-tryptone, 5 g/L yeast extract, 10 g/L sodium 
chloride in distilled water and autoclaved at 120°C for 25 minutes) supplemented 
with 100 µg/ml of ampicillin (Fermentas).  The agar plates were incubated 
overnight in a 37°C incubator.  A colony was aseptically inoculated into a 50 ml 
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falcon tube that contained 5 ml of LB broth supplemented with 100 µg/ml of 
ampicillin.  The inoculated medium was incubated in a shaking incubator at 37°C, 
200 rpm for 8 hours.  The 5 ml culture was transferred to 200 ml of LB 
supplemented with 100 µg/ml of ampicillin and then incubated at 37°C, 200 rpm for 
16 hours.  
 
2.2.6 Isolation of DNA plasmids using the Qiagen Maxiprep kit 
The Qiagen plasmid purification kits (Whitehead Scientific, SA), used in this study 
are based on a modification of an alkaline lysis procedure and the subsequent 
binding of plasmid DNA to an anionic-exchange resin in low salt and pH 
conditions.  DNA is eluted with a high-salt solution, and the purified DNA is 
concentrated and desalted by precipitation using isopropanol. 
 
The overnight culture that was obtained as the final product of E.coli 
transformation was retrieved from the shaking incubator and the bacterial cells 
were harvested by centrifugation at 6000 × g for 15 minutes at 4°C.  The bacterial 
pellet was resuspended in 10 ml of resuspension buffer P1 (50 mM Tris-Cl, pH 
8.0, 10 mM EDTA, 100 µg/ml RNase A).  Lysis buffer P2 (10 ml; 200 mM NaOH, 
1% SOS (w/v) was added and mixed gently by inverting 4-6 times followed by an 
incubation period of 5 minutes at room temperature.  Chilled neutralisation buffer 
P3 (10 ml; 3.0 mM potassium acetate, pH 5.5) was added, the solution was mixed 
immediately by gentle inversion and incubated on ice for 20 minutes.  The solution 
was centrifuged at 4°C, at 2000 × g for 30 minutes.  The DNA plasmid containing 
supernatant was removed immediately and centrifuged once more under the same 
conditions.  A Qiagen-tip 500 was equilibrated by applying 10 ml of equilibration 
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buffer QBT (750 mM NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol (v/v); 0.15% 
Triton X-100 (v/v)) where the column was allowed to empty completely by gravity 
flow.  The supernatant was then applied to a Qiagen-tip and allowed to enter the 
resin by gravity flow.  The Qiagen-tip was washed twice with 30 ml of wash buffer 
QC (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15 % isopropanol) and then the DNA was 
eluted with elution buffer QF (1.25 M NaCl; 50 mM Tris-Cl, pH 8.5, 15 % 
isopropanol (v/v)).  The DNA was precipitated by adding 10.5 ml of room 
temperature isopropanol to the eluted DNA.  The DNA solution was immediately 
pelleted by centrifugation at 15 000 × g for 30 minutes at 4°C.  The supernatant 
was carefully decanted and the DNA pellet washed with 5 ml of 70% ethanol and 
further pelleted at 15 000 × g for 10 minutes.  The supernatant was decanted 
ensuring that the pellet was not dislodged.  The DNA pellet was air-dried for 5-10 
minutes and redissolved in a suitable volume of distilled water.  The DNA was 
stored at -20°C. 
 
2.2.7 Co-transfection of HEK 293T cells 
The Env-pseudotyped virus was generated by co-transfecting HEK 293T cells with 
the env-expressing ZM53 plasmid and the backbone plasmid pSG3Δenv.  Here 2.8 
× 106 HEK 293T cells were pre-seeded in a 6 cm tissue culture treated petri dish 
which contained 10 ml GM and incubated in appropriate growth conditions.  A 
DNA mix was prepared by adding 10 µg of the ZM53 plasmid and 10 µg of 
pSG3Δenv.  The mix was filled up to a final volume of 300 µl with serum and 
antibiotic starved GM.  Superfect (60 µl, Invitrogen, SA) was added to the DNA, 
mixed by vortexing and incubated for 15 minutes at room temperature.  The cells 
were retrieved from the incubator and the cell monolayer was washed with 5 ml of 
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PBS (Sigma Aldrich, SA).  GM (3 ml) was added to the DNA-Superfect solution 
and transferred to the cell monolayer.  The cells were incubated for 3 hours under 
normal growth conditions.  The medium was aspirated and the cell monolayer 
washed with PBS (5 ml) to remove residual DNA and transfection reagent.  The 
cells were fed with GM (10 ml) and incubated for 48 hours under normal growth 
conditions. 
 
2.2.8 Harvesting of Env-pseudotyped virus 
Forty eight hours post transfection, the culture supernatant containing the 
pseudovirus was clarified from cells by filtration using a 0.45 µm filter.  Aliquots 
were made and stored at -80°C. 
 
2.2.9 Env-pseudotyped virus titration 
The titration of env-pseudotyped viruses is imperative for the optimal performance 
of HIV-1 inhibition assays that were carried out in this study.  The dosage of Env-
pseudotyped virus to use in the inhibition assay was determined using the 50% 
tissue culture infectious dose (TCID50) method.  The TCID50 refers to the amount 
of Env-pseudotyped virus with the ability to infect 50% of the inoculated cultures of 
TZM-bl cells. 
 
The TCID50 was determined by adding 100 µl of GM into all wells of a 96-well, flat 
bottom tissue culture treated plate (The Scientific Group, SA).  Env-pseudotyped 
virus (25 µl) was added to the first four wells (column 1, rows A-D) of the 96-well 
plate where 5-fold serial dilutions were carried out by the transfer of 25 µl of the 
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pseudovirus to upper wells for a total of 11 dilutions.  Column 12 of the 96-well 
plate was used for the cell control where no Env-pseudotyped virus was added.  
TZM-bl cells (104 cells/100 µl in GM containing DEAE dextran (Sigma Aldrich, SA) 
to a final concentration of 20 µg/ml in each well) were added to all wells of the 96-
well plate.  The plate was incubated for 48 hours in a 37°C, 5% CO2 and 85% 
humidity environment.  The detection system that was used for the assay was the 
Bright Glo luciferase substrate (Anatech Instruments, SA).  Here the infectivity of 
the Env-pseudotyped virus was measured according to the expression of the Luc 
reporter gene in the TZM-bl cells after a single round of viral infection.  The 
substrate functions to lyse the cells and cause luminescence of successfully 
infected cells.  The relative luminescence units (RLU) were quantified using the 
Tecan Infinite F500 microplate reader.  The TCID50 dose that was used was 
calculated using Assay Excel Macros provided online by (Montefiori, 2009).  Here 
the TCID50 dosage is calculated based on the Reed and Muench formula (shown 
in Appendix B-3) where a cut-off value of RLU<2.5 times the background was 
considered negative for the calculation (Reed, 1938).  The Env-pseudotyped 
viruses that yielded between 15 000 and 150 000 RLU equivalents was selected.   
 
2.3 Assembly and characterisation of a home built photo-translocation 
system 
A commercial Fianium FemtoPower 1060-fs laser (Fianium, UK) and additional 
components were used to assemble a photo-translocation setup (described in 
section 2.4) with the ability to facilitate the targeted delivery of ARV drugs into 
TZM-bl cells.  Extensive characterisation of the laser beam was undertaken to 
ensure that the laser specifications obtained in our laboratory matched those 
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reported by the manufacturer.  The characterisation experiments which were 
investigated namely; the repetition rate, central wavelength, pulse duration, beam 
quality and beam diameter of the laser beam were crucial for the accurate 
assembly of the photo-translocation setup.  Optimal functionality of the laser and 
assembled setup would facilitate successful ARV drug delivery in the planned 
experiments. 
 
2.3.1 Validation of laser pulse trains and measurement of the repetition rate 
To confirm the consistency of the pulses emitted by the laser, the laser pulse 
trains were observed and their repetition rates determined.  Using an oscilloscope 
(Tektronix), the constantly varying signal voltages of the laser were observed.  
Here a sub-miniature version A (SMA) cable was used to connect the laser 
oscillator to the oscilloscope.  The oscilloscope was set at a frequency of 150 MHz 
and a current of 50 Ohms.  Pulse trains were taken on 5, 50 and 20 nanosecond 
per division (ns/div) time scale and 50, 50 and 200 millivolts per division (mV/div) 
amplitude, respectively. 
 
2.3.2 Central wavelength and spectral bandwidth measurements 
The central wavelength and spectral bandwidth of the Fianium laser were 
measured to validate that the peak intensity of the laser pulses was at a 
wavelength of 1064 nm as specified by the manufacturer.  This was done by 
aligning an ocean optics spectrometer in the path of the laser beam.  The 
spectrometer was connected to a computer to allow capturing of the output data.  
Subsequently the data was plotted on Excel and the resultant spectrum was used 
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to calculate the bandwidth of the laser at full width half maximum (FWHM).  FWHM 
is where the full width of the laser and half of the laser intensity resides.    
 
2.3.3 Pulse duration measurement 
The success of photoporation as discussed earlier is affected by the pulse 
duration of the laser.  The most commonly employed method for such a 
measurement is frequency-resolved optical gating (FROG) which involves 
spectrally resolving the signal beam of an autocorrelation measurement (Trebino 
et al., 1997).  However, in this study a home built autocorrelator was assembled 
and consisted of a beam splitter (BS), mirrors M1, M2 and M3, a nonlinear crystal, a 
lens with a known focal length and finally a spectrometer that was connected to a 
computer to enable capturing of the FROG trace.  All lenses and mirrors used in 
this study were obtained from Comar, UK.  Figure 2.1 shows the self-assembled 
FROG experimental setup. 
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Figure 2.1: Arrangement of the FROG set up.   
The NIR Gaussian beam was emitted by a Fianium FemtoPower laser where two pulses of the beam were 
created by a beam splitter.  The red arrows indicate the path that was taken by each of the created beams.  
BS, beam splitter; M, mirror; and L, lens. 
 
The BS separates the incoming pulse into two identical pulses which take different 
paths.  The pulse that is refracted by the BS is further refracted by M1 and M2.  
The path length of this pulse remains constant while the path length of the second 
pulse is adjustable.  After the pulse is transmitted by the BS, the pulse is refracted 
back to the BS by M3 which is mounted on an electronically movable stage 
(Newport, SA).  The pulse is refracted by the BS and both pulses are focused by a 
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lens, L1, with a focal length of 100 mm onto the nonlinear β-Barium Borate crystal 
(BBO, CASIX, UK).  When the two pulses overlap spatially and temporarily in the 
BBO crystal, a FROG signal with double the frequency of the incoming pulses is 
generated.  A high repetition HR4000 spectrometer (Ocean optics) was placed in 
the path of the autocorrelation signal and multiple measurements of the pulses are 
taken over a wide range of pulse lengths and captured on the computer. 
 
2.3.4 Beam quality measurement 
The propagation of a laser can be approximated by assuming that the beam has 
an ideal Gaussian intensity profile which generally corresponds to the theoretical 
transverse electromagnetic mode (TEM00).  Real life lasers are however not truly 
Gaussian and to accommodate the variance a beam quality factor, M2, has to be 
defined.  M2 allows us to measure the amount of deviation of a laser beam from a 
theoretical Gaussian.  This is done using a technique that incorporates a positive 
lens with known focal length and a charge coupled device (CCD) camera.  The 
laser beam was focused through a lens with a focal length of 300 mm.  Using the 
BeamGage laser profiler the diameter of the beam was measured at equal 
distance intervals (30 mm) from the lens (Figure 2.2). 
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Figure 2.2: Experimental setup of the beam quality.   
The output beam was focused through lens L1 with a focal length (f) of 300 mm.  A CCD camera was 
positioned at 30 mm distance intervals along the beam’s axis of propagation (z) when beam diameter 
measurements were captured. 
 
2.3.5 Beam diameter measurements 
To ensure that a diffraction limited spot required for the photo-translocation of 
drugs was generated successfully, beam diameter measurements were taken at 
different points of the photo-translocation setup.  For the measurement a 
USBSP206U CCD camera was utilised and placed along the path of the beam. 
Using BeamGage software (Spiricon Laser Beam Diagnostics) the beam was 
captured, recorded and the transverse intensity profile was displayed using the 
second moment (D4σ) technique.  The beam diameter was measured at the laser 
output, post beam expansion and at the beam focus. 
 
2.4 Assembly of the photo-translocation setup 
Following laser characterisation, the optical setup that was used for the 
translocation of ARV drugs into HIV-1 permissive cells was assembled.  A 
schematic illustration of the dual objective photo-translocation setup that was 
assembled is shown in Figure 2.3.  A NIR, pulsed Gaussian beam was emitted by 
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a Fianium FemtoPower laser.  The diameter of the input laser beam was 
expanded to overfill the back aperture of a 60 X air objective (Nikon) lens with a 
numerical aperture (NA) of 0.8.  To expand the beam, a two-plano convex lens 
telescope was positioned in the path of the beam as it propagated.  The laser 
beam was expanded by a predetermined magnification factor, M, defined by the 
following expression:         
            
1
2
f
f
M                (2.1) 
Where f2 is the focal length of L2 and f1 is the focal length of L1.  The lenses that 
were used, L1 and L2, have focal lengths of f1 = 50 mm and f2 = 200 mm 
respectively.   
 
An electronic shutter (Newport, SA) was placed before the telescope on the path 
of the beam to regulate the time that the beam was exposed to the cell membrane 
at the sample plane situated on a XYZ translation stage.  After expansion the 
beam was reflected by mirror M1 and then by a periscope composed of mirrors M2 
and M3.  The beam was reflected by a dichroic mirror, DM, which also transmitted 
white light from the Koehler illumination system.  The Koehler illumination system 
was composed of a series of apertures and lenses (L3, L4, and L5) and served to 
facilitate the uniform illumination and imaging of the sample being viewed.  The 
white light and laser light bounced off mirror M4 and subsequently focused by a 
tube lens (TL, f=175 mm) and directed onto the sensor of a CCD camera.   
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Figure 2.3: Arrangement of the photo-translocation set up.   
Division 1, beam expansion; division 2, elevation of the laser beam; division 3, illumination system; division 4, 
sample magnification and imaging system.  The NIR Gaussian beam was emitted by a Fianium FemtoPower 
laser where the beam travelled through an electronic shutter before being expanded by a two lens telescope 
to fit into the back aperture of a 60X objective lens.  L1-5, lenses; M1-4, mirrors; DM, dichroic mirror; NA, 
numerical aperture; LDW, long distance working; TL, tube lens; CCD, charge coupled device. 
 
 
 
 
Page 56 of 152 
 
2.5 Evaluation of the photo-translocation system  
2.5.1 Trypan blue photo-translocation into TZM-bl cells 
In early studies of photoporation Stevenson et al., (2006) made use of a viability 
dye which is normally impermeable to the cell membrane, trypan blue, in order to 
confirm that photoporation of cells resulted in the perforation of the cell membrane 
without compromising the integrity of the cell.  In this study, trypan blue was used 
not only to confirm translocation of exogenous materials into the cell’s cytoplasm 
but more importantly, it was used to indicate which laser-to-cell exposure time and 
laser power levels would be optimal for drug delivery while retaining the integrity of 
the cell.  An area of the cells to be treated was clearly marked using a permanent 
marker and the same field was viewed under the microscope before, during and 
after the cells were treated with the laser.  TZM-bl cells that were photoporated 
successfully were expected to internalize the viability dye and retain the blue 
colour of the dye while cells not treated with the laser would remain intact and not 
internalise the trypan blue molecules.  The laser-to-cell exposure time and power 
level that achieved such results was considered optimal for the delivery of drugs.  
The properties of dead cells in the demarcated area to be treated were noted. 
 
In these experiments, TZM-bl cells (3 × 103 cells) were seeded in 200 µl of GM in a 
35 mm diameter glass bottom tissue culture treated petri dish with a 10 mm 
diameter working area (Wirsam Scientific, SA).  The cell cultures were incubated 
overnight in normal growth conditions.  The monolayer was washed in 1 × PBS 
and submerged in 20 µl of 0.4% trypan blue exclusion dye and the sample 
diameter was covered with a 8 mm diameter type-1 sterile coverslip (Labotech, 
SA).  The targeted photo-translocation was administered to individual cells in 3 
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doses within the selected area where different power levels (40 mW to 100 mW 
increasing each time with increments of 10 mW) and different laser-to-cell 
exposure times (30 ms to 1 second increasing each time by 10 ms).  Following 
laser irradiation, the monolayer was washed with PBS to remove residual trypan 
blue.  Thereafter, the treated cells were viewed using a CCD camera connected to 
an Olympus microscope (Wirsam Scientific, SA).  The cell cultures were viewed 
using the bright field microscope setting where images of the cells were captured. 
 
2.5.2 Photo-translocation of ARV drugs into TZM-bl cells 
The photo-translocation of ARV drugs like that of trypan blue consists of two steps.  
The first step involved the photoporation of the cell and the second step involved 
the actual translocation of these exogenous agents into the cell cytoplasm.  A 
sample of TZM-bl cells (2 × 103) was seeded and prepared as described in section 
2.5.1.  The cell monolayer was submerged in 20 µl of neat GM (without FBS and 
PEST) which contained a final concentration of 20 µg/ml of tenofovir, efavirenz or 
nevirapine.  In order to differentiate between laser assisted drug delivery and the 
spontaneous uptake of the drugs by the cells, control sample dishes were also 
prepared.  Each laser treated experimental dish was accompanied by a control 
dish which is referred to as a drug control (DC).  The DC contained cells 
submerged in either one of the three ARV used in the study, but in these controls 
the delivery of drugs was not facilitated by laser irradiation.  Following three doses 
of laser irradiation using 60 mW as the optimal power level and 50 ms as the 
laser-to-cell exposure time, the monolayer was washed with 1 × PBS.  The cell 
monolayer was supplemented with 200 µl of GM and incubated overnight.  
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2.5.3 HIV-1 inhibition assay 
To detect the successful photo-translocation of ARV drugs into TZM-bl cells, the 
Bright Glo luciferase assay kit was used.  Alongside the preparation of the photo-
translocation experimental and DC dishes, additional controls were prepared in a 
96-well, flat bottom, transparent, Corning microtiter plate (The Scientific group).  
These controls were the cell control (CC), the virus control (VC) and the positive 
control (PC).  The PC contained cells infected with Env-pseudotyped virus and 
exposed to the drugs for the full duration of incubation (48 hours).  The 96-well 
plate that contained the additional controls was incubated alongside the glass 
bottom dishes which contained the laser irradiated cells and the DC.  This was 
done to ensure that all the wells of the 96-well plate and the glass bottom dishes 
were treated under the same conditions in an identical manner.  
 
GM (60 µl) was added to each well and an additional 25 µl was added to the CC to 
compensate for the volume of the Env-pseudotyped virus.  The appropriate drug 
was added to the PC to a final concentration of 20 µg/ml which resulted in a 5 
times dilution of the drug.  Env-pseudotyped virus (25 µl with a dosage of 100 
TCID50) was added to all wells except those of the CC.  An additional 50 µl of GM 
which contained DEAE dextran to a final concentration of 20 µg/ml was added to 
each well.  DEAE dextran was added in order to increase HIV-1 binding to cells in 
turn enhancing the infectivity of the Env-pseudotyped viruses.  After an incubation 
period of 48 hours in normal cell growth conditions, the RLUs were measured 
using a multiplate reader.  In this assay, viral Tat protein induces the expression of 
the reporter genes within TZM-bl cells.  Luciferase activity is directly proportional 
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to the number of infectious virus particles that were present in the initial inoculum 
that were capable of cell entry and viral genome integration.  
 
2.5.4 Cytotoxicity assay     
There exist a variety of assays for the investigation of metabolic and physical 
conditions of cells.  In this study we showed the effects of irradiating TZM-bl cells 
with a laser in the presence of various ARV drugs using the Cell Titer 96 Non-
Radioactive cell Proliferation assay (Anatech Instruments).  The assay is a 
colorimetric method used to estimate the number of viable cells in culture post 
laser irradiation.  The assay contains MTT tetrazolium salts [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] which readily penetrates viable eukaryotic 
cells.  Viable cells with an active metabolism are able to convert MTT into a purple 
coloured formazan product.  Dead cells have an inability to convert MTT to 
formazan rendering formazan formation a useful marker for the detection of viable 
cells.   
 
In the MTT assay, 2 × 103 TZM-bl cells were seeded per well, and prepared as 
described in section 2.5.1.  To evaluate the effects of laser irradiation, the cell 
monolayer was washed with 1 × PBS following a 24 hour incubation period.  The 
monolayer was submerged in 20 µl of GM not containing FBS or PEST.  To 
differentiate between the metabolic and physical conditions of TZM-bl cells that 
were exposed to the laser, control cell cultures were prepared.  Each laser treated 
experimental dish was therefore accompanied by a control dish which is referred 
to here as the LC.  The LC contained cells submerged in GM without FBS and 
PEST.  To evaluate if the combination of the laser with the respective drugs did 
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not cause cytotoxic effects on the cells, experimental (EXP) and DC dishes were 
prepared for each of the three drugs as described in section 2.5.2.  Additional 
controls namely; a CC, PC and Triton X-100 (TC, Sigma Aldrich, SA) were 
prepared in a 96-well multiwell plate and incubated alongside the glass bottom 
dishes.  Triton X-100 is a non-ionic surfactant which is used to lyse cells where the 
agent leads to the disruption of the cell membrane for protein purification.  When 
used in large amounts or exposed to cells for prolonged periods of time, the cells 
die.  In such cases triton X-100 leads to the disruption of the compartments and 
integrity of the lipid membrane due to the disruptive action of the triton X-100 
molecule’s polar head group on the hydrogen bonding present within the cells 
membrane (Koley et al., 2010). 
 
Following three doses of laser irradiation using 60 mW as an optimal power level 
and 50 mW as the laser-to-cell exposure time the monolayer was washed with 1 × 
PBS.  The cell monolayer was supplemented with 200 µl of GM and incubated 
overnight.  GM (50 µl) was added to all wells except for PC and TC wells where 
GM was added with respective drugs used in the study accordingly to the 
appropriate final concentration.  An additional 50 µl of GM was added to all wells 
of the 96-well plate, EXP and LC dishes were incubated for 48 hours in normal cell 
growth environmental conditions.  MTT dye solution (15 µl) was added to each 
well followed by a 4 hour incubation period in appropriate growth conditions.  After 
incubation, 100 µl of the solubilisation solution or stop mix was added to all wells 
and incubated at room temperature for an hour.  Without causing any bubble 
formation, the solutions within the wells were mixed by pipetting and solutions of 
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the glass bottom dishes were transferred to the 96-well plate.  Using a multi-plate 
reader, absorbance profiles were recorded at a wavelength of 570 nm.  
 
2.6 Statistical analyses 
The data in this study was analysed using Mathematica version 9 for windows 7, 
Matlab, Excel and Origin.  Non-parametric one-way analysis of variance was used 
to investigate the statistical significance of data.  Statistical difference is shown in 
the results by an asterisk.  Statistical methods performed are discussed 
accordingly with reported results in chapter 3. 
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3. Results 
3.1 Laser beam characterisation 
This study aimed to evaluate the ability of a home-built photo-translocation DDS 
setup to more efficiently deliver ARV drugs tenofovir, efavirenz and nevirapine into 
TZM-bl cells compared to the absence of a DDS.  In order for the setup to be built, 
the laser device was characterised to assess adequate functionality.  Following full 
characterisation and assembly of the setup, the ARV drugs were translocated into 
the mammalian cells by diffusion through a pore generated by the precise 
alignment of a tightly focused laser onto the cell membrane. 
 
3.1.1 Validation of laser pulse trains and determination of pulse repetition 
rate  
The monitoring of pulse trains using an oscilloscope allowed us to determine 
whether the laser master source is a passively mode-locked fiber laser at a 
repetition rate in the MHz range.  The spectrums displaying the pulse-to-pulse 
stability of the Fianium laser master source is shown in Figure 3.1.  Irrespective of 
the set time and amplitude on the oscilloscope, the pulses showed temporal 
stability in real time.  The oscillator repetition rate obtained from the oscilloscope 
was 76.5 MHz.  This repetition rate is comparable to that of 76.6 MHz reported by 
the manufacturer.    
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Figure 3.1: Validation of laser pulse trains.  
Pulse trains were validated at varying time scales and amplitudes; a) 5 ns/div, 50 mV/div; b) 20 ns/div, 200 
mV/div and c) 50 ns/div, 50 mV/div respectively. Conversion factors 2e
-9
, 2.5e
-9 
and 2e
-9
 were used for the 
scaling of the time for graphs a, b and c respectively. Conversion factors 0.002, 0.001 and 0.002 were used 
for the scaling of the amplitude for graphs a, b and c respectively. 
 
3.1.2 Central wavelength and spectral bandwidth measurements 
The central wavelength refers to the central operating wavelength of a laser.  This 
wavelength is defined by a peak mode measurement and is where the optical 
power of the laser resides.  Figure 3.2 shows that the central wavelength of the 
laser was 1063.8 nm.  The obtained central wavelength is within the acceptable 
range of 1063 to 1065 nm given by the manufacturer.  The central wavelength is 
indicated on the spectrum in Figure 3.2 by the red vertical line.  
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Figure 3.2: Spectrum showing the measured central wavelength and bandwidth of the Fianium laser.   
The central wavelength is indicated by the red line while the calculation of the bandwidth at full width half 
maximum (FWHM) is indicated by the green line. 
 
The bandwidth of the laser was calculated using the spectrum at FWHM.  The 
calculated bandwidth of 5.2 nm is acceptable for the Fianium laser as it falls within 
the range of 5.0 to 15.0 nm stipulated by the manufacturer.    
 
3.1.3 Pulse duration measurement 
The temporal profile of the Fianium FemtoPower laser was measured at the laser 
output.  This measurement is important for this study as it makes it possible to 
account for the time that a single pulse is exposed to each cell.  In turn the 
efficiency of drug delivery and the integrity of the cell can be accounted for with 
respect to time (Amat-Roldan et al., 2004, Trebino et al., 1997).   
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Following the acquisition of a FROG signal, a spectrum of the signal was acquired 
(Figure 3.3) by using a spectrometer.    
 
Figure 3.3: Spectrum of the measured FROG signal where intensity was plotted against wavelength. 
 
The central wavelength of the obtained FROG signal was 532 nm as anticipated.  
The signal was generated when the two incident pulses overlapped in the crystal.    
 
FROG measurements involve the recording of tens or thousands of spectra for 
different arrival time differences between the two pulses.  The resultant 
measurement is displayed in a spectrogram with a colour scale of the intensity as 
a function of time delay and optical frequency or wavelength.  Two sets of 
measurements were taken in this study first using a BBO nonlinear crystal which 
was cut to function optimally at a wavelength of 800 nm.  Secondly, the 
measurements were taken using a potassium titanyl phosphate (KTP) crystal cut 
to function optimally at a wavelength of 1064 nm.  The time that it took to measure 
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each pulse using both nonlinear crystals is shown in the spectrograms in Figure 
3.4.   
 
Figure 3.4: Spectrograms showing the time it took to measure each pulse.  
a) shows results obtained when a BBO crystal was used and b) when a KTP crystal was used in the FROG 
optical setup.  In the intensity indicator bar shown on the right of the spectrograms, red is indicative of a high 
intensity while blue is indicative of a low intensity. 
 
The time taken to measure a single pulse was converted to the actual length of the 
pulse using the following equation: 
Pulse duration = t × scanning velocity × 2 × 3.33667 × 10-12 × 0.707          (3.1)  
 
where t is time, scanning velocity is the velocity of the translation stage, 2 
represents that the pulse that was reflected by mirror M3 travelled the same 
distance twice, 3.33667 × 10-12 is the speed of light converted to mm/s and finally 
0.707 is the deconvolution factor of a Gaussian beam.  By substituting x  values 
into the equation, the pulse duration at FWHM was measured to be 10 ps.  This 
pulse length did not compare with that obtained by the manufacturer of 210 fs.  
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The spectrograms obtained for the pulse duration measurements are depicted in 
Figure 3.5. 
 
Figure 3.5: FROG traces of the pulse duration measurement.  
A BBO crystal was used in a) and b) while a KTP crystal was used for measurements of c) and d).  In a) and 
c) FROG traces of wavelength versus time are shown and in b) and d) the temporal distribution of the 
Gaussian pulse where the FROG traces were summed over various wavelengths is shown.  The intensity was 
plotted against time.   
 
3.1.4 Determination of the beam quality  
The measurement of M2 is an integral part of characterising a laser.  The beam 
quality of a TEM00 Gaussian beam is M
2=1 however, this beam quality is 
impossible to achieve with real life lasers.  The quality of real life lasers is ideal 
when M2>1, but as close to 1 as possible.  The lower the value of the quality factor 
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the greater the quality of the beam (Siegman, 1993).  Essentially, M2 describes 
how close to a perfect Gaussian a real life laser is. 
 
As Gaussian beams propagate through space, the beam radius varies with 
distance by, 
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where z is the distance propagated by the beam from where the wavefront is flat, λ 
is the wavelength of laser light, ω(z) is the beam width and ω0 is the width at the 
beam waist (Saleh et al., 1991).  To calculate the beam quality factor equation 3.2 
can be expanded to the following quadratic equation: 
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The derivation of equation 3.3 from equation 3.2 is shown in appendix A-1. 
 
The data obtained from the beam quality measurements were fitted to a two order 
polynomial where the square of the beam radius was plotted against the distance 
along the propagation axis.  The two order polynomial therefore takes the form, 
CBzAzY  2      (3.4) 
 
Page 69 of 152 
 
where Y is the square of the beam waist and A, B and C are the coefficients of the 
polynomial fit.  Comparing the terms of equation 3.3 to those of equation 3.4 we 
obtained that 
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Equation 3.3 can then be compared to the fitted equation to determine the beam 
quality, beam waist and the z position as follows: 
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The parameters that were measured from the quadratic fit are shown in Table 3.1 
and the accompanying graph showing the square of the measured beam radii as 
the laser propagated is shown in Figure 3.6. 
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Table 3.1: Measured beam parameters for the Fianium FemtoPower laser 
Parameter Measured 
M2 1.15 
ω0 (mm) 0.24 
z0 (mm) 307 
M
2
; Beam quality factor 
ω0; Beam radius 
z0; z position where the diffraction limited spot is situated 
 
 
Figure 3.6: Graph showing the calculation of the beam quality.   
The black squares are of the values representing the square of the measured beam widths at various 
distances from the lens.  The red trendline represents a fitting of the data points and is based on the quadratic 
equation shown in the graph.  ω, beam radius and z, distance away from  the lens. 
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These results demonstrate that the Fianium FemtoPower laser produces a good 
quality beam.  The obtained quality factor M2 = 1.15 compares with that of M2 = 1.1 
which was specified by the manufacturer.  Also, the manufacturer stated that an 
acceptable range for the beam quality factor is 1.0 ≤ M2 ≤ 1.3 where M2 cannot be 
smaller than 1.0 and cannot be greater than 1.3.   
 
Figure 3.7 illustrates how the diameter of the beam changes as it propagates 
along the z axis.  The z position is that where a diffraction limited spot is attained.  
The diameter of the beam decreases as the beam approaches the focus of f = 300 
mm and increases as the beam propagates away from the focus.  The z position 
calculated as shown above and displayed in Table 3.1 of z0 = 307 mm compares 
with the focal length of the lens that was used for this measurement.      
 
 
Figure 3.7: Images of the laser beam as it propagated along the z axis.   
The images shown were captured at various distances from the lens indicated by z = 3 cm to z = 57 cm in 
intervals of 9 cm. 
 
3.1.5 Beam diameter measurements 
The discussion and specifications of beam propagation characteristics necessitate 
that the beam diameter is defined.  The beam diameter is most often defined as 
the diameter where the intensity of the beam has fallen to 1/e2 (13.5%) of its peak 
value (Andrews et al., 2005).  In this study the beam diameter was measured at 
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various points of the photo-translocation setup to ensure that the desired effects of 
the optical setup were met.  Eighty six percent of the beam is carried within a circle 
with a radius ω(z) and is regarded as the beam width along the propagation 
direction of the beam.  The beam diameter, 2ω0, is also referred to as the spot 
size.  Firstly, the spot size was measured at the laser output and yielded the 
results shown in Figure 3.8. 
 
Figure 3.8: Beam diameter measurement at the laser output.   
a) Image of the cross section of the laser beam.  This is the image to which the statistical data in b) was 
based.  The obtained spot size from the statistical data is highlighted by the red oval. 
 
A theoretical model of the beam waist measurement was carried out and the 
following Gaussian exponential function was plotted: 
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where )(zI  is intensity as a function of propagation distance z .  The resultant 
intensity distribution plot is depicted in Figure 3.9. 
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Figure 3.9: Intensity distribution of the laser beam as a function of z, propagation distance (in mm).   
The data was captured at the laser output.  The red trendline is representative of a fitting of the data points 
acquired using a beam profiler and is based on the Gaussian exponential equation. 
 
Table 3.2: Measured spot size and beam radius of the Fianium FemtoPower laser against the theoretical 
estimate of the beam radius.   
Measured 2ω0 (mm) Measured ω0 
(mm) 
Estimated ω0 (mm) Estimated ω0 
standard error 
1.3 0.65 0.51 0.0016 
2ω0; Beam diameter 
ω0; Beam radius 
 
The difference between the measured and estimated beam waist was not 
significant (Table 3.2).  The obtained beam diameter of 1.3 mm compares well 
with that of 1.2 mm which was given by the manufacturer.  The measurement was 
also within the acceptable range of 1 – 2.5 mm given by the manufacturer.  This 
result was optimal and allowed us to continue with the assembly of the photo-
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translocation setup.  Using the measured beam diameter, the size of the beam 
was expanded to overfill the back aperture of the objective lens that was used to 
focus the beam to a diffraction limited spot.  The laser beam was expanded by a 
predetermined magnification value, M (equation 2.1). The resultant beam after 
expansion is shown in Figure 3.10.  Table 3.3 describes the magnification factor 
used for the expansion of the beam diameter using a two lens telescope.  The 
table also shows the expected beam diameter and the measured beam diameter 
after magnification of the spot size was done.  
 
Figure 3.10: Beam diameter measurement after the beam was expanded.   
a) shows an image of the cross section of the expanded laser beam.  This is the image to which the statistical 
data in b) was based.  The obtained spot size from the statistical data is highlighted by the red oval. 
 
Table 3.3: Measurement of the magnification factor for the expansion of the beam spot size, as well as the 
measured and expected spot sizes following beam expansion. 
Measured 2ω0 (mm) 
at laser output 
Magnification 
factor (M) 
Measured 2ω0 (mm) 
after expansion 
Expected 2ω0 
(mm) 
1.3 M = 200 / 50 = 4 4.9 1.3 × 4 = 5.2 
2ω0; Beam diameter 
M; Magnification factor 
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Figure 3.11: Intensity distribution of the laser beam as a function of z, propagation distance (in mm).   
The data was captured after the beam diameter was expanded.  The red trendline is representative of a fitting 
of the data points acquired using a beam profiler and is based on the Gaussian exponential equation. 
 
After the laser beam was focused with the objective lens, the beam diameter was 
measured once again.  The obtained spot size is depicted in Figure 3.12. 
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Figure 3.12: Beam diameter measurement after the beam was focused through the objective lens.   
a) Shows an image of the cross section of the focused laser beam.  This is the image to which the statistical 
data in b) was based.  The obtained spot size from the statistical data is highlighted by the red oval. 
 
Figure 3.13: Intensity distribution of the laser beam as a function of propagation distance.   
The data was captured at the laser focus.  The red trendline is representative of a fitting of the data points 
acquired using a beam profiler and is based on the Gaussian exponential equation. 
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Table 3.4: Measured spot size and beam radius of the focused Fianium FemtoPower laser against the 
theoretical estimate of the beam radius.   
Measured 2ω0 (mm) Measured ω0 
(mm) 
Estimated ω0 (mm) Estimated ω0 
standard error 
0.11 0.055 0.05 0.002 
2ω0; Beam diameter 
ω0; Beam radius 
 
3.2 Assembly of photo-translocation set up 
Following full characterisation of the Fianium laser, the photo-translocation setup 
was assembled according to the schematic provided in chapter 2.  An image of the 
completed setup used in the study is depicted in Figure 3.14. 
 
Figure 3.14:  Image of the completed home-built photo-translocation setup. 
 
post 
 
clamp 
mount 
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The optical components of the set up were mounted and firmly screwed into a 
vibration damped (floated) table with optical supports such as clamps, posts and 
mounts and depicted if Figure 3.14.  The alignment of a laser through the 
microscope objective is crucial to allowing a diffraction limited spot.  This is critical 
for the production of a high quality three dimensional single-beam for the poration 
of the cell membrane.  The expanding and collapsing of the airy disc formed as a 
result of the circular back aperture of the microscope objective is best illustrated by 
a video.  Here, we however show a sequence of images displaying the focusing of 
the airy disc (Figure 3.15).    
 
Figure 3.15 (a) to (d): Images illustrating the expansion and collapsing of an airy disk during focusing.  These 
images were taken using a 60X objective lens. 
 
5 µm 5 µm 
5 µm 5 µm 
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The obtained airy disc was optimal for the photo-translocation studies as it was 
free of spherical aberrations, coma and astigmatism.  To ensure that the laser 
beam was not clipped as it propagated through the microscope objective and that 
it was aligned accordingly, the airy disc was evaluated in greater detail.  From 
Figure 3.15 it is clear that the airy disc is not clipped as perfect rings are observed.  
The obtained airy disc was compared to that shown in literature by (Ming Lee et 
al., 2007).  Figure 3.16 shows a sequence of images resembling those obtained in 
this study for the collapsing and expanding of the airy disc (Lee et al., 2007). 
 
Figure 3.16: Image showing the focusing of an airy disc through collapsing and expanding.  
Copied from (Ming Lee et al., 2007). 
 
Figure 3.17(a) depicts an example of a focused laser which is optimal for optical 
manipulation setups such as photo-translocation systems.  The Figure also shows 
airy discs with unwanted aberrations (Figure 3.17(b) – (d)) during assembly of a 
functional optical system.   
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Figure 3.17: (a) Example of a focused, well aligned airy disc while (b) to (d) show examples of unwanted 
spherical aberrations.   
Copied from (Lee et al., 2007).  
 
These images assert that the photo-translocation setup assembled in this study 
was optimally aligned and suited for the photo-translocation studies due to the 
absence of spherical aberrations on the resultant airy disc. 
 
3.3 Photo-translocation of trypan blue viability dye 
Trypan blue, a membrane impermeable viability dye was photo-translocated into 
TZM-bl cells under varying experimental parameters.  Different exposure times of 
the laser to the cells and varying power levels were used in order to determine 
which parameters would not compromise the integrity of the cells.  The marked 
area containing the cells that were treated was checked before and after laser 
treatment.  The experiments were also carried out to demonstrate that the delivery 
of exogenous materials into cells can be achieved using a laser source. 
Subsequent to trypan blue photo-translocation, the optimal experimental 
parameters were used for the delivery of the selected ARV drugs into the HIV-1 
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permissive cell line.  The bright-field microscope images in Figure 3.18 show the 
effects of photo-translocating trypan blue at a constant exposure time of 50 ms 
and varying power levels of 100, 80 and 60 mW. 
 
Figure 3.18: Bright field images of TZM-bl cells photo-porated in the presence of a membrane impermeable 
viability dye, trypan blue.   
100 µm 10 µm 
10 µm 10 µm 
20 µm 20 µm 
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Photo-translocation was carried out at 1064 nm, 76 MHz, 10 ps and 50 ms.  In a) and b) laser irradiation was 
done at a power level of 100 mW.  More specifically a) shows photo-translocated cells where the white arrow 
indicates the treated cells. These images were taken using a 4X microscope objective. In b) irradiated cells 
are shown using a 40X microscope objective and arrows indicate cell blebbing.  In c) and d) photo-
translocation of the dye was done at 80 mW and the images were taken at a 40X magnification.  In c) cell 
damage in the form of cell blebbing is shown and indicated by white arrows while d) shows cells that were not 
irradiated by the laser.  In e) and f) laser assisted delivery of trypan blue was done at 60 mW.  In e) irradiated 
cells which internalized the dye 5 minutes after photoporation are indicated by white arrows while f) shows 
untreated cells which did not internalize the dye.  These images were taken using a 20X microscope objective. 
 
In all three instances it was evident to the user that outside of the treated cells 
trypan blue was not internalized by the adjacent non-irradiated cells as these cells 
retained their natural transparent appearance.  These, and all laser based 
experiments in this study, were done live and visualised in the computer as they 
took place.  As such, these experiments would have been better reported as a 
video rather than in images as done in this report (outside the scope of this 
dissertation).  At first glance 100 mW did not appear to exhibit negative effects on 
the integrity of the cells when the images were captured using a 4X magnification 
(Figure 3.18 (a)).  Upon magnifying the images 10 times by using a 40X 
magnification (Figure 3.18 (b)), cell blebbing where a cytoplasmic spillage 
occurred was observed.  Cell blebbing is seen in the images as circular extensions 
of the cells.  Image 3.18 (b) appears to be darker than 3.18 (a) because residual 
trypan blue which remained after washing the cell monolayer with 1X PBS was 
more apparent when higher magnifications were used for imaging.  At higher 
magnifications more detail on the cells was also observed. 
 
When 80 mW was used as the photoporation power level, cell blebbing was 
observed amongst irradiated cells (Figure 3.18 (c)).  This is contrary to when the 
cells were not treated by the laser in Figure 3.18 (d) where no cell blebbing was 
observed.  Due to the residual trypan blue in the cell sample it is not clear which 
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cells retained the blue colour as a result of photo-translocation but it is clear that 
there is cell blebbing as a result of laser irradiation.  Upon lowering the laser power 
to 60 mW no cell blebbing was observed amongst laser treated cells.  Irradiated 
cells took up the blue dye which appears to be situated in the nucleus of the cells 
(Figure 3.18 (e)).  The colour intensity of the internalised dye seems to be lower 
when the power level used is 60 mW compared to when laser treatment was done 
at higher powers.  A higher amount of the dye appears to have been taken up at 
higher laser powers. 
 
From these results we concluded that the optimal parameters to use for the photo-
translocation of ARV drugs were to treat the cells with 3 doses of laser treatment 
at 60 mW with the shutter exposure time of 50 ms per shot.     
 
3.4 Photo-translocation of ARV drugs into TZM-bl cells 
Since the use of impermeable dyes is a gold standard for optimizing parameters 
such as laser power, exposure time and location of irradiation (Stevenson et al., 
2006, Pravan et al., 2011), the parameters for trypan blue were extrapolated to 
drug delivery for the purposes of this study (where parameters are unknown).  The 
ability of the newly assembled photo-translocation setup to assist in enhancing the 
intracellular delivery of ARV drugs was evaluated by monitoring the inhibitory 
effect on viral integration of a subtype C env-pseudotyped virus (ZM53), using a 
TZM-bl cell based assay.  In this study 150 cells in a population of 2000 TZM-bl 
cells (7.5%) were treated with the laser.    
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The ability of DDS-assisted tenofovir, nevirapine and efavirenz delivered by photo-
translocation to inhibit ZM53 replication in TZM-bl cells was quantified by 
measuring luciferase activity in RLUs.  As shown in Figures 3.19 and 3.20 below, 
the photo-translocation of both tenofovir and nevirapine into TZM-bl cells 
respectively contributed to a higher inhibition of ZM53 compared to when drug 
delivery was not facilitated by the laser during the time where the cells were 
exposed to the drugs for 30 minutes.  For both tenofovir and nevirapine delivery 
into TZM-bl cells the PCs showed the highest percentage of drug inhibition (refer 
to Table 3.5).  The formula for the calculation of % inhibition is shown in Appendix 
B-1. The VCs for both tenofovir and nevirapine inhibition studies showed the 
highest level of infectivity.  Viral activity and viral inhibition is assessed with 
reference to RLU values where a high RLU value is indicative of low pseudoviral 
inhibition while a low RLU value is indicative of a high pseudoviral by the ARV 
drugs.  Differences in RLU values between the three independent experiments 
shown are attributed to different pseudovirus stocks. 
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Figure 3.19: Bar graph showing the RLU values of the laser assisted delivery of tenofovir.  
For tenofovir (EXP, purple) the cells were exposed to the drug for a period of 30 minutes while being 
irradiated.  Data is shown against cells that were exposed to tenofovir for 30 minutes without laser treatment 
(TC, green), a positive control where the cells were exposed to tenofovir for 48 hours (complete duration of 
HIV-1 inhibition assay, PC, red) and against a negative control (VC, blue) where cells were infected with ZM53 
env-pseudotyped virus in the absence of tenofovir.  EXP, TC and PC were all challenged with ZM53.  In all 
presented instances a higher inhibition of ZM53 was observed when the delivery of the drug was photo-
translocated into the TZM-bl cells as represented by lower RLU values compared to TC.  RLU values 
represent the means ± standard error of the mean (SEM) for three independent experiments done in triplicate 
where error bars represent the SEM (n=3).  The asterisk is a representation of significant difference amongst 
data sets where the standard t-test was used (p<0.05). 
 
 
Figure 3.20: Bar graph showing the RLU values of the laser assisted delivery of nevirapine.  
For nevirapine (EXP, purple) the cells were exposed to the drug for a period of 30 minutes.  Data is shown 
against cells that were exposed to nevirapine for 30 minutes without laser treatment (NC, green), a positive 
control where the cells were exposed to nevirapine for 48 hours (complete duration of HIV-1 inhibition assay, 
PC, red) and against a negative control (VC, blue) where cells were infected with ZM53 env-pseudotyped 
virus in the absence of nevirapine.  EXP, NC and PC were all challenged with ZM53.  In all presented 
instances a higher inhibition of ZM53 was observed when drug delivery was facilitated by a laser as 
represented by lower RLU values compared to NC.  RLU values represent the means ± standard error of the 
mean (SEM) for three independent experiments done in triplicate where error bars represent the SEM (n=3).  
The asterisk is a representation of significant difference amongst data sets where the standard t-test was used 
(p<0.05). 
 
The RLU values obtained following the treatment of TZM-bl cells with efavirenz 
was significantly lower than the virus control in all instances at the utilized drug 
concentration (Figure 3.21).  Both laser treated and untreated cells achieved 99% 
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inhibition of ZM53.  Further, a prolonged exposure of the cell population to 
efavirenz (from 30 minutes compared to 48 hours) resulted in an inhibition 
percentage of 98% (Table 3.5).  
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Figure 3.21: Bar graph showing the RLU values of the laser assisted delivery of efavirenz.  
For efavirenz (EXP, purple) the cells were exposed to the drug for 30 minutes.  Data is shown against cells 
that were exposed to efavirenz for 30 minutes without laser treatment (EC, green), a positive control where the 
cells were exposed to efavirenz for 48 hours (complete duration of HIV-1 inhibition assay, PC, red) and 
against a negative control (VC, blue) where cells were infected with ZM53 env-pseudotyped virus in the 
absence of efavirenz.  EXP, EC and PC were all challenged with ZM53.  In all presented cases efavirenz was 
able to successfully inhibit infection by ZM53 with no superiority to laser assisted drug delivery or drug to cell 
exposure time.  RLU values represent the means ± SEM for three independent experiments done in triplicate 
where the SEM is represented by error bars.  No significant difference amongst data sets was observed when 
the standard t-test was used (p<0.05). 
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Table 3.5: The percentage inhibition values of photo-translocated ARV drugs against drug taken up naturally 
by the cells with drug to cell exposure times of 30 minutes and 48 hours by measuring luciferase activity in 
HIV-1 infected TZM-bl cells. 
 % INHIBITION 
Sample Tenofovir Nevirapine Efavirenz 
PC 97 ± 26 99 ± 11 98 ± 22  
TC/NC/EC 39 ± 14 29 ± 9 99 ± 36 
EXP 64 ± 5 54 ± 6 99 ± 16 
PC: Drug control where the cells were exposed to the drugs for 48 hours. 
TC: Tenofovir control where the cells were exposed to tenofovir for 30 minutes. 
NC: Nevirapine control where the cells were exposed to nevirapine for 30 minutes. 
EC: Efavirenz control where the cells were exposed to efavirenz for 30 minutes. 
EXP: Experiment where the laser was used to porate the cell membrane to allow diffusion of tenofovir, 
nevirapine and efavirenz. 
 
3.5 Cytotoxicity assay 
ARV drugs were delivered into TZM-bl cells through a laser induced pore on the 
cell membrane.  The resultant percentage viability was measured relative to a drug 
control where the cells were exposed to the respective drug for 48 hours and 
against cells exposed to the drug for 30 minutes.  In addition, a cell control (CC) 
with cells that were not treated with the laser or with drugs was kept under optimal 
growth conditions for the duration of the entire experiment.  Cells which were 
treated with 1% Triton X-100 were included as a positive control.  As shown in 
Figures 3.22 to 3.25 the viability of irradiated cells in all instances is greater than 
70%.  When the cells were exposed to the drugs for 30 minutes the percentage 
viabilities ranged from 53% to 100%.  Further, in all instances the positive control 
showed low levels of viability ranging from 1% to 3%.  Cells that were not treated 
with the laser or the drug (laser control (LC), Figure 3.22) showed a percentage 
viability of 100%.  A percentage viability of 86% was observed in the tenofovir drug 
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control (Figure 3.23) while both nevirapine and efavirenz controls (Figure 3.24 and 
3.25 respectively) showed significant differences (p < 0.05) to when drugs were 
exposed to the cell population for 30 minutes both in the presence and absence of 
laser irradiation.  Table 3.6 shows the percentage viability for each reported 
instance (the formula used to calculate % viability is shown in Appendix B-1). 
 
 
Figure 3.22: MTT assay for laser irradiated cells.   
TZM-bl cells were irradiated with a laser at 1064 nm, 60 mW for a 50 ms exposure time per dose of a total of 
three doses per cell.  Untreated cells (CC, blue), were kept under optimal growth conditions for the duration of 
the experiment, cells were treated with 1% Triton X-100 (TX, orange) as a positive control and laser treated 
cells (EXP, green) compared to cells that were not irradiated by the laser (LC, grey).  Both laser treated and 
untreated cells showed % viabilities of 96.5 and 100% respectively.  Error bars represent the SEM (n=3).  No 
significant difference amongst data sets was observed when the standard t-test was used. 
 
 
Page 89 of 152 
 
 
Figure 3.23: MTT assay for the photo-translocation of tenofovir into TZM-bl cells.   
Tenofovir was photo-translocated into TZM-bl cells (EXP, red) and compared to the tenofovir control (TC, 
green) where the delivery of tenofovir was not assisted by the laser and tenofovir was exposed to the cells for 
30 minutes.  Additional controls where TZM-bl cells were exposed to the drug (DC, grey), 1% Triton X-100 
(TX, orange) for 48 hours and a cell control (CC, blue) where the cells were not treated with the laser or ARV 
drugs while kept under optimal growth conditions for the duration of the experiment were included.  In all 
instances either than TX, % viabilities of above 75% were achieved after treatment.  Error bars are a 
representation of the SEM (n=3).  No significant difference amongst data sets was observed when the 
standard t-test was used. 
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Figure 3.24: MTT assay for the photo-translocation of nevirapine into TZM-bl cells.   
Nevirapine was photo-translocated into TZM-bl cells (EXP, red) and compared to the nevirapine control (NC, 
green) where the delivery of the drug was not assisted by a laser and the cell-to-drug exposure time was 
limited to 30 minutes.  Additional controls where TZM-bl cells were exposed to 1% Triton X-100 (TX, orange) 
and a drug control (DC, grey) for 48 hours, and a cell control (CC, blue) where the cells were not treated with 
the laser or ARV drugs while kept under optimal growth conditions for the duration of the experiment were 
included.  In all instances where the cells were treated with the laser and/or exposed to the drug for 30 
minutes, % viabilities of above 50% were achieved with laser treated cells showing greater levels of viability 
than those not treated with the laser.  When cells were treated with nevirapine for 48 hours (DC, grey) the 
viability of the cell population was severely compromised.  A positive control where cells were treated with 1% 
Triton X-100 (TX, orange) was also included.  Error bars are a representation of the SEM (n=3).  Using the 
standard t-test an asterisk is a representation of significant difference. 
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Figure 3.25: MTT assay for the photo-translocation of efavirenz into TZM-bl cells.   
Efavirenz was photo-translocated into TZM-bl cells (EXP, red) and compared to the efavirenz control (EC, 
green) where the delivery of the drug was not assisted by a laser and the cell-to-drug exposure time was 
limited to 30 minutes.  Additional controls where TZM-bl cells were exposed to 1% Triton X-100 (TX, orange), 
a drug control (DC, grey) and a cell control (CC, blue) where the cells were not treated with the laser or ARV 
drugs while kept under optimal growth conditions for the duration of the experiment were included.  In all 
instances where the cells were treated with the laser and/or exposed to the drug for 30 minutes, % viabilities 
of above 50% were achieved with laser treated cells showing greater levels of viability than those not treated 
with the laser.  When cells were treated with efavirenz for 48 hours (DC, grey) the viability of the cell 
population was severely compromised.  A positive control where cells were treated with 1% Triton X-100 (TX, 
orange) was also included.  Error bars are a representation of the SEM (n=3).  Using the standard t-test an 
asterisk is a representation of significant difference between data sets. 
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Table 3.6:  Percentage viabilities of laser irradiated cells and ARV photo-translocated cells assessed using 
the MTT assay.  
 % VIABILITY  
Sample Laser alone Tenofovir Nevirapine Efavirenz 
CC 81.8 ± 0.0 100 ± 0.0 100 ± 0.0 74.6 ± 0.0 
TX 2.4 ± 0.7 1.0 ± 0.1 1.0 ± 0.2 1.1 ± 0.2 
DC - 86 ± 1.3 2.0 ± 0.8 -2.1 ± 0.4 
LC/TC/NC/EC 100 ± 9.2 77 ± 13 53 ± 6.7 100 ± 6.1 
EXP 96.5 ± 12.4 82 ± 20 73 ± 3.3 93.8 ± 10.9 
TX: Triton-x 100 - positive control where the cells were exposed to Triton-X 100 for 48 hours. 
DC: Drug control where the cells were exposed to the drugs for 48 hours. 
LC: Laser control where the cells were not treated with a laser and placed in the same environment as the 
cells treated by a laser for 30 minutes. 
TC: Tenofovir control where the cells were exposed to tenofovir for 30 minutes. 
NC: Nevirapine control where the cells were exposed to nevirapine for 30 minutes. 
EC: Efavirenz control where the cells were exposed to efavirenz for 30 minutes. 
EXP: Experiment where the laser was used to porate the cell membrane to allow diffusion of tenofovir, 
nevirapine and efavirenz. 
CC: Cell control where the cell were not treated with the laser and the drugs.  These cells were kept under 
optimal growth conditions throughout the duration of the experiments. 
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4. Discussions 
The applicability of photo-translocation as a DDS to successfully deliver 
therapeutic agents to target cells was demonstrated by the ability of a home built 
fs laser to enhance the uptake of selected ARV drugs into HIV-1 permissive cells. 
 
4.1 Characterisation of the laser towards the assembly of a functional photo-
translocation setup 
The more effective translocation of ARV drugs into TZM-bl cells relies on the 
efficiency of the assembled photo-translocation set up as well as accurate 
functioning of the laser beam.  The functionality of the laser can be assessed by 
characterization which takes into account some laser parameters.  These 
parameters include beam shape, beam quality and how the beam may be altered 
as it propagates in free space and through the optical system.  In this study a 
pulsed laser was used and features such as pulse duration, central wavelength 
and spectral wavelength had to be taken into consideration during 
characterisation.  It is possible to determine these characteristics experimentally 
which is important because it gives us information that is necessary during the 
assembly of the optical system and when preparing for the drug delivery 
experiments in the study.  These characteristics are often predetermined by the 
manufacturer and given to the customer together with the laser system’s manual.  
Acquiring more accurate values for these parameters experimentally is important 
to verify the standard specifications provided by the manufacturer as well as to 
ensure that the optical setup is assembled using precise measurements.  The 
experimental setup has to be assembled to encourage the optimal operation of the 
laser especially where it interacts with the cell membrane. 
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4.1.1 Mode-locking nature of the Fianium FemtoPower laser 
Lasers are able to oscillate on various longitudinal modes with frequencies that are 
spaced equally by intermodal spacing.  These modes usually oscillate 
independently but external means can be adopted to couple the modes and lock 
their phases together.  When the phases are locked together a periodic pulse train 
is formed (Bahaa et al., 1991).  A mode locked laser ensures that there is stability 
amongst the emitted pulses.  According to the consistency of the pulses as they 
propagate along the z axis it was observed that the laser is passively mode locked 
(Figure 3.1).  A repetition rate of 76.6 MHz was obtained for the pulses of the laser 
used in this study.  High repetition rates such as this are recommended for 
photoporation as they can yield up to several millions of pulses at a single laser 
exposed spot on the cell membrane (Vogel et al., 2005).     
 
4.1.2 Laser pulse durations 
The measurement of the pulse duration was acquired and carried out using FROG 
as stipulated in section 2.3.3.  A FROG measurement provides information about 
time, wavelength as well as intensity.  As the two pulses generated by the BS 
propagate towards the nonlinear crystal, one of the pulses is delayed in time by 
increasing or decreasing the path length compared to the other.  By overlapping 
the two pulses in space and time within the nonlinear crystal, light with twice the 
frequency of the input laser was produced.  This light is mostly referred to in this 
study as the FROG signal.  In the case where the two laser pulses do not overlap 
in time within the nonlinear crystal no autocorrelation signal would be obtained 
(Trebino et al., 1997).  
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The pulse duration of 10 ps obtained from the FROG measurements is not ideal 
for photoporation experiments as ps pulses have been reported to yield low 
poration efficiencies and can result in negative mechanical effects on the cell 
(Schinkel et al., 2008).  Due to financial constraints we were not able to purchase 
an alternative fs laser source and due to time constraints we were not able to 
return the laser to the manufacturer for further investigation.  We however 
continued to use the Fianium laser to perform the drug delivery experiments that 
were intended for this study as we believed that the findings of this study can 
contribute to the advancement of the fields of biophotonics and drug delivery.  The 
effects of using a fs laser against a ps laser are discussed further in section 4.5. 
  
4.1.3 Beam quality contribution to the efficiency of photo-translocation 
In this study an optimal quality of the beam was essential because it influences the 
success of the photo-translocation of the ARV drugs.  A high quality laser has a 
smooth wavefront which means that focusing the laser with an objective lens will 
result in a plane wavefront which is desirable for this study.  In a case where the 
quality of the beam is low, the wavefront would be scrambled resulting in difficulty 
when focusing the beam (Siegman, 1990).  The ability to acquire a diffraction 
limited spot is the essence of photo-translocation as it is with a tightly focused 
laser that a pore can be efficiently generated on the cell membrane.  Further, it is 
through the generated pore that the drugs are able to diffuse into the cell.  A 
scrambled wavefront at the beam focus would therefore interfere with the photo-
translocation of the drugs.  
 
Page 96 of 152 
 
According to the obtained M2 result of 1.15, the Fianium laser is approximately 
1.15 times diffraction limited as compared to a true Gaussian beam profile 
(Siegman, 1993).  The quality of the Fianium laser (based on the obtained M2 
value) is of a good standard as it is close to 1.0 which is the M2 value of a true 
Gaussian beam. 
 
4.1.4 Functionality of assembled photo-translocation setup 
During assembly where optics were placed accordingly following the schematic 
depicted in chapter 2, the alignment of the laser was critical to ensure functionality 
of the complete set up.  As the beam propagated through the optical elements of 
the setup, care was taken to ensure that the laser landed on the centre of all the 
optics.  This ensured that the laser was not clipped and remained circular and 
propagated straight and levelled.  To achieve this, pin holes were strategically 
placed along the setup where passage through all the pin holes confirmed that the 
laser beam was at the centre of the optics and that it was levelled in terms of 
height as it propagated.  In the setup, cages were also employed to hold some of 
the optical components making it easier to align the laser (as shown in Figure 
3.14).   
 
4.2 Establishment of an HIV-1 inhibition assay 
Laser assisted delivery of exogenous materials into cells has been explored in 
various sectors of biomedicine and biotechnology.  As mentioned in earlier 
sections, the efficiency of the technology has previously been quantified by the 
delivery of dyes and fluorescent DNA plasmids (Stevenson et al., 2006, Tirlapur et 
al., 2002).  In this study, our focus was not only to evaluate the efficiency of the 
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technology but was primarily to prove and show for the first time that the 
technology can be applied to enhance the therapeutic effects of ARV drugs that 
have been photo-translocated into HIV-1 permissive cells.  This proof-of-principle 
study therefore made use of a HIV-1 env-pseudotyped inhibition assay to show the 
technology is applicable to enhancing drug delivery in vitro. 
 
This primarily quantitative assay is widely utilized to measure the effect of various 
inhibitors such as antibodies (Montefiori, 2005), aptamers (Mufhandu et al., 2012) 
and other lead compounds (ARV drugs) on viral replication.  The assay is 
standardised and reproducible making it an ideal tool for the primary screening of 
the effects of photo-translocation also taking into account its reported levels of 
accuracy (Polonis et al., 2008).  The assay can be performed using peripheral 
blood mononuclear cells (PBMCs) and replication competent virus derived from 
PBMCs.  These viruses make use of an error prone RT in order to replicate thus 
representing a heterogeneous viral population.  For reproducibility purposes and 
ease of comparison we used a homogeneous viral population of an env-
pseudotyped viral strain, ZM53 (Polonis et al., 2008).  The advantage presented 
by using a pseudovirus includes the exclusion of variables such a growth kinetics 
which could influence the results and compromise the primary purpose of this 
study. 
 
Here we chose to use ZM53 as the env-pseudotyped virus to assist in evaluating 
that the ARV drugs were indeed internalised by the TZM-bl cells during photo-
translocation.  The pseudovirus is clinically relevant as it is a subtype C viral strain 
and as such dominant in Sub-Saharan Africa.  ZM53 is categorised by Seaman et 
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al., (2010)  as a tier 2 env pseudovirus when they assessed the stringency of a 
panel of 109 molecularly cloned HIV-1 env pseudoviruses.  Compared to tier 1 
viruses which are easily neutralised, ZM53 is a more resistant pseudovirus to 
neutralisation (Seaman et al., 2010).  It is therefore considered clinically relevant 
and ideal for screening purposes in this study. 
 
The ARV drugs that were chosen in the study namely; tenofovir, nevirapine and 
efavirenz are FDA approved drugs for the treatment of HIV-1.  At the time the 
study was conducted, these drugs were highly recommended as a regimen for the 
first line defence against HIV-1 infection in South Africa.  As such, these selected 
drugs were locally relevant for the purposes of this study. 
 
4.2.1 Fate of the ARV drugs used in the study 
The ARV drugs used in this study are orally administered, immediate release 
tablets.  These drugs therefore disintegrate rapidly and are dissolved to facilitate 
the release of the medicament (Jaimini, 2013).  They are absorbed in the GIT 
which is also a major barrier to the bioavailability of drugs.  The GIT contains 
metabolising enzymes, efflux proteins and physiochemical properties which 
contribute to the hindrance to the absorption of the drugs (Pang, 2003). 
 
The primary site for the metabolism of both nevirapine and efavirenz is the liver.  
The liver contains cytochromes (CYP) P450 which are proteins characterised by 
possessing an absorption maximum at 450 nm after carbon monoxide (CO) 
binding.  These proteins which comprise of a superfamily of specific gene products 
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that contain different specificities catalyse the oxidative metabolism of endogenous 
and exogenous substances.  Molecular isoforms of CYP are induced when 
exposed to chemical stimuli (Khatsenko et al., 1993). 
 
Nevirapine and efavirenz are such chemical stimuli as they are moderate inducers 
of CYP (Riska et al., 1999, Cristofoletti et al., 2013).  Both drugs are metabolised 
through biotransformation by the isoenzymes CYP3A4 and CYP2B6 (Cristofoletti 
et al., 2013, Erickson et al., 1999, Riska et al., 1999, Adkins et al., 1998).  By 
virtue of being inducers, these drugs are able to increase the rate of hepatic 
metabolism of other drugs by increasing the transcription of CYP messenger tRNA 
(Back et al., 2003).  Consequently, the production of more enzymes occurs and a 
decrease in the plasma concentration of the drug being metabolised by the 
induced pathway takes place (Wood et al., 2001).  Both nevirapine and efavirenz 
are eliminated in the urine after glucoronidation to water soluble conjugates for 
rapid elimination from the body (Cammett et al., 2009). 
 
Unlike nevirapine and efavirenz that are metabolised by CYP, tenofovir disoproxil 
fumarate (TDF) is not metabolised by these enzymes but rather undergoes several 
intracellular processes.  TDF is a prodrug of tenofovir which goes through esterase 
hydrolysis for the removal of the ester group in the compound after being 
administered orally.  Tenofovir requires intracellular phosphorylation to the active 
moiety (Cristofoletti et al., 2013).  It is taken up by the cells where it is 
phosphorylated by cellular nucleoside diphosphate kinases to the active 
diphosphate form.  The activation of tenofovir takes place in both active and 
resting cells. 
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4.3 Effects of ARV photo-translocation on the inhibition of ZM53 env-
pseudotyped virus replication 
The primary objective of this study was to show that a laser can be used as an 
effective DDS.  This was done by assisting the uptake of ARV drugs by an HIV-1 
permissive cell line.  Subsequently, a ps laser source was employed to create a 
pore on the cell membrane through which higher amounts of drugs were expected 
to enter the cell compared to natural drug uptake by cells by active diffusion 
(Gerber, 2000).  As mentioned, TZM-bl cells are able to take up ARV drugs 
naturally so the superiority in laser assisted drug delivery was demonstrated 
through the resultant inhibition percentage of ZM53 when the drug-to-cell 
exposure time is limited to 30 minutes.  During this 30 minute period ± 150 cells in 
a total of 2000 pre-seeded cells per sample were photo-porated.    
 
The photo-translocation of tenofovir and nevirapine resulted in enhanced viral 
inhibition.  In both cases the percentage of viral inhibition was 25% greater than 
when TZM-bl cells took up the drug naturally without the assistance of a laser in 
the same time period.  Future studies of the work should investigate mechanisms 
either than photo-translocation and active diffusion which could be contributing to 
the significant difference observed between irradiated and non-irradiated cells 
after treatment of only 7.5% of the cell population.  The same result was however 
not obtained when efavirenz was photo-translocated into the cells.  Instead, TZM-
bl cells were able to rapidly take up efavirenz irrespective of laser facilitation.  The 
percentage viral inhibition of ZM53 in both comparable instances of 30 minute 
drug-to-cell exposure periods was 99%. 
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The mode of action of tenofovir is such that the analogue competes with 
endogenous DNA-triphosphate to hinder RT activity.  Nevirapine and tenofovir on 
the other hand involves non-competitively binding to the RT enzyme.  In all three 
of the drug cases, the result of their interference prevents RT from converting viral 
RNA to viral DNA (Sosnik et al., 2009).  The manner in which drugs interact with 
the body is referred to as pharmacokinetics.  The behaviour of efavirenz in this 
study may be explained by this concept which speaks to the absorption, transport, 
distribution, metabolism or the manner in which a drug is excreted form the cell 
(Wood et al., 2001). 
 
With a long half-life of 40-45 hours and a wide distribution among various body 
compartments, efavirenz has found wide application in the treatment of HIV-1.  
However, one of the challenges of efavirenz is its association with variable 
responses amongst different individuals and even failure to therapy in some 
patients (Ward et al., 2003).  Efavirenz has also been reported to possess low 
stability in turn compromising its administration, absorption and biodistribution 
(Sosnik et al., 2009).  In this study TZM-bl cells were able to efficiently take up 
efavirenz.  The susceptibility of individuals to diseases as well as how individuals 
respond to drugs varies.  Due to the activity and expression of CYPs displaying 
individual differences, the pharmacokinetics of efavirenz show inter-individual 
variability (Adkins et al., 1998).     
 
The inter-individual variability of efavirenz is seen mostly in the CYP2B6 which is 
the main isoenzyme responsible for the metabolism of efavirenz.  The variability is 
a result of the polymorphic variants of CYP2B6 which leads to different 
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functionality of the isoenzyme between different patients.  The variability can also 
be accounted for by population variables such as age and gender (Marzolini et al., 
2001).  To explain the possible reason for the ability of TZM-bl cells to metabolise 
efavirenz with such efficiency may be attributed to the genetic properties of HeLa 
cells as such, genotyping the HeLa cells in the future may account for the obtained 
result. 
 
Efavirenz is metabolised through hydroxylation by CYP2B6 (Bienvenu et al., 2014) 
whose presence has been reported to be more prevalent in African Americans 
than in Caucasians (Cholewinska, 2007).  Through this observation it becomes 
clear that the photo-translocation of drugs as a DDS may be selective in 
functionality depending on the pharmacokinetics of the delivered drug and the host 
genetics in the treated individual.  This highlights that in developing a DDS, the 
effects of pharmacogenetics and pharmacokinetics should be taken into 
consideration.  Due to the genetic background of the TZM-bl cells, the DDS 
demonstrated in this study was able to contribute to an elevated viral inhibition of 
tenofovir and nevirapine but did not have an effect when efavirenz was photo-
translocated.  It is therefore unclear if other cells will respond in a similar manner 
to the laser facilitated delivery of ARV drugs.  This requires further investigation 
where other cell lines, different donors and different cell types such as CD4+ T 
cells which are major HIV-1 target cells should be treated using a laser as a DDS. 
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4.4 Effects of laser irradiation and ARV photo-translocation on TZM-bl cell 
viability 
The final aim of this study was to confirm that no toxicity resulted from the laser 
treatment of the cells when the laser was used on its own and in conjunction with 
ARV drugs selected for the study.  The standard and classical method for 
assessing viability within a cell population is trypan blue exclusion.  This visual 
method (making use of light microscopy) assesses the late apoptotic and necrotic 
stages of viability detection where viable cells have an intact cell membrane and 
can therefore exclude the entry of trypan blue (Strober, 2001).  The MTT assay 
used in this study is an analytical biochemical procedure where mitochondrial 
activity is measured as reflected by the conversion of the tetrazolium salt, MTT, 
into formazan crystals (van Meerloo et al., 2011).  The MTT assay is 
advantageous compared to the trypan blue exclusion test because it operates at a 
metabolic level.  As such, cells that present with intact cellular membranes with a 
slow or malfunctioning metabolism can be detected by the MTT assay as cells that 
are not viable (St-Louis Lalonde et al., 2013). 
 
The laser was used to porate cells in the absence of drugs and the resultant 
measured cell viability was 96.5 ± 12.4%.  This means that when used on its own 
at an output power of 60 mW and a laser-to-cell exposure time of 50 ms per shot, 
treated cells did not show negative reactions to photoporation.  This result is 
similar to that of St-Louis Lalonde et al., (2013) where they tested the viability of 
melanoma cells in Roswell Park Memorial Institute (RPMI) 1640 medium following 
irradiating them with a 1064 nm, 5 ns pulsed laser source at 1 J/cm2.  St-Louis 
Lalonde et al., (2013) also used the MTT assay to evaluate the viability of the cell 
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populations treated in their study where they obtained constant viabilities of above 
95%.  In the absence of laser treatment slightly higher viabilities were observed 
amongst the TZM-bl cell population although not significantly different. 
 
 
The viability of the cells was again evaluated post photo-translocation of the 
respective ARV drugs.  In all instances cell viabilities were greater than 70% at the 
photo-translocated ARV drug concentrations utilised.  The ARV drug 
concentrations used were based on 50% inhibitory concentrations (IC50s) of the 
drugs as reported in literature (Cheeseman et al., 1993, McRae et al., 2006); as 
such we did not expect to observe cytotoxic effects in any of the photo-
translocated drugs compared to when drugs were allowed to diffuse into the cells 
on their own.  This was indeed the case for the tenofovir DC (86 ± 1.3%) but not 
for nevirapine (2 ± 0.8%) and efavirenz (-2 ± 0.4%) DC’s.  Here, a significant 
difference in cell viabilities was observed compared to when the nevirapine (73 ± 
3.3%) and efavirenz (94 ± 10.9%) was photo-translocated and exposed to the cell 
population for 30 minutes.  This unexpected result may be because the IC50s 
adapted from the literature were based on in vivo rather than in vitro studies taking 
into consideration that clinical drug dosages are significantly higher than those 
administered in vitro.  Clinically, this is necessary to ensure that target sites 
receive an adequate amount of drug to be able to result in the desired therapeutic 
effect as majority of the drug is expected to interfere with areas of the body that 
are not intended thus not requiring exposure to the drugs. 
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The percentage viabilities observed for the laser control (LC) and when the cells 
were porated in the absence of ARV drugs were greater than the % viabilities of 
CC (see Table 3.6).  This was also the case when efavirenz was administered to 
the cells and the drug-to-cell exposure time was 30 minutes both in the absence 
and presence of laser treatment (see Table 3.6).  These results are common when 
the MTT viability assay is used (Soares et al., 2013, Golden et al., 2009, Melo et 
al., 2012, Barahuie et al., 2014, Kehoe et al., 2013).   
 
These results highlight the potential advantages of using a DDS for the delivery of 
therapeutic drugs.  Here, nevirapine and efavirenz were highly toxic when exposed 
to the cell population for prolonged periods of time (48 hours).  This is contrary to 
when the exposure time was decreased to 30 minutes.  In the case of nevirapine, 
after targeting only ± 150 cells in a population of 2000 cells in a 30 minute period, 
an enhanced level of viral inhibition was observed.  On the contrary, efavirenz 
showed no preference to laser irradiation or exposure time where inhibition of viral 
replication was concerned.  In light of the percentage viability results, it is apparent 
that the cells exposed to the drugs for 48 hours may have not been viable after 
photo-translocation of the drugs which means that the observed percentage 
inhibitions were due to the fact that the cells were not metabolically viable after the 
incubation period and may have also been dead, and incapable of supporting viral 
replication.  This observation is true for both nevirapine and efavirenz.   
 
From this we can deduce that a decrease in drug-to-cell exposure periods and 
photo-translocation of drugs during this period contributes to enhanced cellular 
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percentage viabilities while still contributing to enhanced viral inhibition in the case 
of nevirapine.    
 
4.5 ps versus fs laser sources 
The technology of photo-translocating extracellular material has been shown to 
yield the best result when a fs laser source is used (Mthunzi et al., 2010, Tirlapur 
et al., 2002, Uchugonova et al., 2008, Zeira et al., 2003).  In this study the laser 
used was reported by the manufacturer to have a path length of 210 fs.  In our 
hands the laser pulse length was measured to be 10 ps which is contrary to the 
manufacturer’s measurement of 210 fs.  We therefore used a ps laser source for 
this study.  The efficiency of fs laser sources was confirmed by Tirlapur et al., 
(2002) where they observed high precision microsurgery of CHO cells where vital 
cellular function remained intact.   
 
In our experiment, the use of ps laser pulses was appropriate in the facilitation of 
photo-translocation of the extracellular materials with minimal damage exerted on 
the treated cell population.  Similarly, Schinkel et al., (2008) used a ps laser 
source in their study where the obtained results were satisfactory.  The low energy 
levels of the laser (60 mW) during experiments was below the threshold for 
dielectric break-down in water which means that shock waves may have been the 
cause of the openings on the cell membrane (Noack et al., 1998).  The 
mechanism of photoporation with a ps laser source is plasma formation resulting 
from linear absorption while the mechanism of fs laser sources is multiphoton 
plasma formation (Vogel et al., 2005).  The main disadvantage of ps laser sources 
besides the possible mechanical effects when high laser energies are used is the 
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complexity that is experienced in generating high repetition rate ps laser sources 
(Omatsu et al., 2007).  The laser used in this study is commercially available so 
difficulties in generating the high repetition rates of the laser source were not an 
issue for our purposes.   
 
4.6 Limitations of the study 
Photo-translocation of drugs in this study was carried out one cell at a time.  In a 
time period of 30 minutes ± 150 cells were porated.  The single cell treatment 
nature of the technology is a limitation as it does not allow for the treatment of 
large cell populations.  In this study the ability to treat the entire cell population in 
each sample would have led to a more accurate comparison of the positive control 
and the cells where the laser was used to assist ARV drug delivery.  In future, an 
additional control experiment comparing drug concentrations before and after the 
uptake of drugs in both the populations treated with the laser and those not 
exposed to the laser should be carried out.  Such an experiment would serve to 
prove that there is indeed a difference between photo-translocation of drugs as 
opposed to when photo-translocation is not administered.  We believe that the 
ability to treat entire cell population would have led to percentage inhibitions 
similar to the positive control in a short drug-to-cell exposure time.  
 
This limitation was also observed by Marchington et al., (2010) where they 
suggested and demonstrated that an automated system in the form of a 
microfluidic device which they used to deliver cells to the focus of a laser could 
lead to a higher throughput of cell treatment.  Although such a technology would 
increase the throughput of photo-translocation it would not be applicable in this 
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study because TZM-bl cells are an adherent cell line.  Such a technology would be 
more suited for the poration of suspension cells such as PBMCs and lymph node 
explants as this study progresses to other cell types. 
 
Antkowiak et al., (2013) has recently demonstrated the use of a computer based 
interface for the targeting and poration of the cell membrane.  The platform 
combines a fast steering mirror and LabView software to create a touch screen 
based interface for the control of photoporations.  The automated system allows 
the experimenter to point-and-transfect target cells by simply touching the cell on 
the screen.  Such a technology would be applicable to this study as it allows for 
photoporation of adherent cells. 
 
Another limitation of the current study is that for successful photoporation to take 
place, accurate alignment of the focused Gaussian beam spot and the focused cell 
membrane must occur.  A slight misalignment leads to a decrease in the efficiency 
of photoporation.  This careful alignment is however time consuming thus 
contributing to the fact that the technology is not high throughput.  To mitigate this 
limitation, Tsampoula et al., (2007) used a non-diffracting light beam known as the 
Bessel beam (BB) in their optical transfection studies. 
 
Section 1.5 outlined the propagation properties of Gaussian beams.  Due to the 
diffractive nature of Gaussian beams they have a short axial distance to which the 
cell membrane is aligned during photoporation (McGloin et al., 2005).  BBs on the 
other hand can be referred to as ‘pseudo non-diffracting” beams as these beams 
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have a narrow rod-like core which is not prone to diffraction over extended 
distances (Dholakia et al., 2008).  Due to this property of the BB, it is possible to 
place the focused cell membrane along any point of the beam thus allowing for the 
treatment of more cells in the sample.  Tsampoula et al., (2007) showed in their 
study that BBs offer photo-transfection at axial distances 20 times greater than 
that of Gaussian beams.  As such, the use of BBs would contribute to the photo-
translocation of ARV drugs into an increased number of cells in turn strengthening 
the accuracy of the study outcomes.        
 
The current proof-of-principle study included a variety of control tests with the aim 
to show that using a DDS has the potential to enhance the treatment of target 
cells.  However, in the study there is no control eliminating the possible effects of 
laser treatment in the absence of the ARV drugs on ZM53 replication, as such, a 
control of this nature should be included in future studies.     
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5. Conclusions and Future perspectives 
5.1 Conclusions 
In this study we assembled and characterised a fully functional photo-translocation 
system to facilitate the delivery of ARV drugs into an HIV-1 permissive cell line, 
TZM-bl cells.  Following photo-translocation the cells were then infected with a 
subtype C Env-pseudotyped virus.  The selective nature of the technology was 
demonstrated by the photo-translocation of trypan blue into targeted TZM-bl cells.  
This proof-of-principle study has demonstrated that a ps laser source can be 
employed to more efficiently deliver ARV drugs into TZM-bl cells and contribute to 
an enhanced level of viral inhibition with little to no compromise to the viability of 
the treated cells.  The delivery of drugs into cells using this technology was 
demonstrated through the amalgamation of a molecular biology assay rather than 
light microscopy.  The study provides preliminary data showing that by employing 
a DDS for the delivery of drugs in a targeted manner, the drug-to-cell exposure 
time can be significantly decreased in turn decreasing the toxic effects of drugs 
especially when drugs are administered in high and otherwise toxic 
concentrations.      
 
5.2 Future perspectives 
As this was a proof-of-principle study to primarily demonstrate the application of a 
pulsed, high repetition laser source for the enhanced delivery of ARV drugs into 
target cells, there is still a lot of work to be done to further optimize the technology 
at an in vitro level with intentions to ultimately progress to in vivo studies possibly 
in mouse models.  The DDS should be tested in the future in different cell lines 
and against varying drug concentrations (including dose-dependent response 
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studies) as well as in varying drug-to-cell exposure periods, with the appropriate 
controls.   
 
To increase the throughput of the technology, the technology should in future be 
automated to enable treatment of the entire cell population at a quicker period of 
time.  This study made use of a Gaussian beam for all experiments, in future the 
photo-translocation of drugs could be done using a BB where the results can be 
compared to those attained using a Gaussian beam. 
  
The results of this study highlighted the importance of taking into consideration the 
pharmacokinetics of a drug and the pharmacogenetics of the patient in drug 
administration.  Although demonstrated in TZM-bl cells, the study should progress 
to deliver more ARV drugs with different modes of action as well as those used in 
the current study in other cell lines and other cell types from blood donors.  For 
example the cell types that could be treated in future include PBMCs, lymph node 
extracts and CD4+ T cells which are a major target cell for HIV.  The ability of the 
technology to contribute to enhanced levels of ZM53 inhibition must be 
interrogated against a panel of env-pseudotyped viruses from different HIV-1 
subtypes in so doing assessing the broad applicability of the technology.  Lastly, 
ZM53 is only capable of one round of infection, as such the technology should in 
future be investigated for its ability to facilitate enhanced viral inhibition against 
replication competent viruses. 
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Appendices 
Appendix A: Derivation of equations 
1. Derivation of beam radius polynomial 
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Appendix B: Formulae 
1. Calculation of % viral inhibition 
 
 
2. Calculation of % viability 
 
3. Calculation of TCID50  
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Appendix C: Clearance Certificate  
 
